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ABSTRACT
SEMAPHORIN 3D SIGNALING IN CARDIOVASCULAR DEVELOPMENT
Haig Aghajanian
Jonathan A. Epstein

Development of the heart is an intricate and complex process. Crucial to this process is
vascular patterning and the signals that properly guide developing vessels.
Consequences of improper patterning can be severe, including life-threatening
congenital heart defects. In this dissertation, I investigate the role of the secreted
guidance molecule semaphorin 3d (Sema3d) in cardiovascular patterning during
development, and attempt to dissect the molecular mechanisms involved in Sema3d
signaling. Using loss-of-function genetic experiments in mice, I model multiple forms of
congenital heart defects such as total anomalous pulmonary venous connections,
transposition of the great arteries, and congenital abnormalities of the coronary vessels.
These mouse models are powerful tools, which I use to investigate the etiology and
morphogenesis of these disorders. Critical to understanding these congenital defects in
these models is precisely deciphering the cellular and molecular mechanisms involved. I
show how Sema3d affects the motility, migration, and adhesion of endothelial cells
through a process of cytoskeletal reorganization, and I identify multiple molecules in the
Sema3d signaling pathway, including a novel holoreceptor comprised of the receptor
tyrosine kinase ErbB2 and semaphorin receptor neuropilin 1. Elucidating the precise
mechanisms of normal vascular development along with pathologic processes is a
necessary step towards future interventions and possible therapeutics.
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Chapter 1 : Introduction

Summary

In this dissertation I explore the role of signaling molecules in patterning the developing
vasculature, and how improper vascular patterning can lead to congenital heart defects.
In this introductory chapter I will discuss how the heart develops and the role vascular
development plays in this process. I introduce general concepts regarding congenital
heart disease and later in the chapter focus on three such disorders; total anomalous
pulmonary venous connection discussed in Chapter 2, congenital abnormities of the
coronary vessels discussed in Chapter 4, and transposition of the great arteries that I will
discuss in Chapter 5. I also introduce the various signaling molecules I will investigate in
later chapters and discuss what is known and not known in relation to cardiovascular
patterning and development. Select passages, tables, and figures in this chapter were
published in a review I co-authored for Cell Metabolism (Epstein, Aghajanian et al.
2015).

Cardiovascular development and congenital heart defects

The heart is the first functional organ to form during embryogenesis. Heart development
(Figure 1.1) begins with the migration of mesodermal precursors away from the primitive
streak to form a bow-shaped structure called the cardiac crescent. This region can be
1	
  
	
  
	
  
	
  

divided into the first heart field, which gives rise to the linear heart tube, and the second
heart field, which gives rise to portions of the atria, the outflow tract and the right
ventricle (Epstein 2010). Initially, the heart consists of two layers; an inner endocardium
and an outer myocardium. Subsequently, the myocardial layer expands and
proepicardial progenitor cells migrate over the surface of the heart, contribute fibroblasts
that invade the myocardial layer, and form the outermost epicardial layer. Complex
asymmetric morphogenetic movements coupled with uneven growth rates contribute to
looping and chamber formation. A series of septation events results in a fully functional
four-chambered heart integrated with systemic and pulmonary circulations (Epstein
2010). This process is facilitated by neural crest cells, which migrate from the dorsal
neural tube and invade the cardiac outflow tract (Kirby, Gale et al. 1983), contributing to
the smooth muscle of the great vessels and which are required for innervation of the
heart (Kirby and Stewart 1983).

All together, the normal development of the heart involves the complex cooperative
interplay of cell migration, proliferation, lineage specification, differentiation, as well as
tight spatial and temporal transcriptional regulation. Any perturbations or abnormalities in
these processes resulting in structural problems of the heart at the time of birth are
known as a congenital heart defect (CHD) or congenital heart disease. Congenital heart
defects are the most common major congenital defects occurring at a rate of 4-8/1,1000
live births (Ferencz, Rubin et al. 1985). CHDs can be broadly classified as cyanotic and
acyanotic. Cyanotic defects are so named because of the blue-grey skin color of affected
neonates caused by the lack of oxygenated blood. This can be caused by right-to-left
shunting (flowing) and the mixing of deoxygenated and oxygenated blood entering the
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systemic circulation. Examples of cyanotic defects include persistent truncus arteriosus,
transposition of the great arteries, and total anomalous pulmonary venous connections,
which I will discuss later in this introduction and in Chapter 2. As the name would
suggest, acyanotic defects do not result in decreased oxygen saturation of the blood and
consist of left-to-right shunting of blood in the heart (atrial and ventricular septal defects;
patent ductus arteriosus) or obstructive defects (pulmonary stenosis; aortic stenosis;
coarctation of the aorta). Additionally, in Chapter 4 I will also discuss a related congenital
abnormality of the coronary vasculature that is associated with CHD.

The causes of CHD can be divided into two basic categories; genetic causes and nongenetic causes. Examples of recognized non-genetic causes of CHD include infectious
diseases (rubella)(Dewan and Gupta 2012), maternal exposure (alcohol,
thalidomide)(Zhu, Kartiko et al. 2009), and environmental teratogens (dioxins, PCBs,
pesticides)(Kopf and Walker 2009). Genetic causes of CHD include single gene
mutations, chromosomal abnormalities, and copy number variations, and have been
found to be autosomal dominant, autosomal recessive, as well as sex-linked (Fahed,
Gelb et al. 2013). The earliest discovered genetic causes of were familial cases of CHD
caused by autosomal dominant or sex-linked mutations, but were limited in resolution.
More recently, animal models of CHD have greatly improved our understanding of the
genetic, cellular, and molecular mechanisms involved in normal cardiovascular
development as well as the etiology and morphogenesis of CHD (Fishman and Olson
1997; Srivastava 2006; Evans, Yelon et al. 2010; Vincent and Buckingham 2010). The
identification of causal genetic variations and understanding the pathobiology of CHD
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are important steps towards future therapies and management of various congenital
heart defects.

Vascular Development

Much of my thesis work pertains to the vascular component of cardiovascular
development and the genetic, cellular, and molecular mechanisms involved in normal
vascular patterning and disease. There are three main vessel systems that together
make up the vascular system (Udan, Culver et al. 2013). The arterial system is made up
of large arteries such as the pulmonary artery and dorsal aorta that carry blood away
from the heart and branch off into progressively smaller diameter arteries, arterioles and
capillaries. The venous system carries blood back to the heart, originating in capillary
beds and moving through progressively larger diameter venules and veins. Finally, the
lymphatic system collects and returns interstitial fluid from the body to the circulation.
This vascular system begins to develop early in embryogenesis in tandem with the
development of the heart.

Vessels can develop in one of two ways. The process of blood vessels forming de novo
from endothelial progenitors is termed vasculogenesis (Risau and Flamme 1995;
Flamme, Frolich et al. 1997). Alternatively, a vessel that sprouts or branches from an
existing vessel is termed angiogenesis (Risau 1997). Vascular endothelial progenitor
cells known as angioblasts are derived from mesodermal cells during gastrulation.
Angioblasts share a common progenitor with hematopoietic progenitors known as
hemangioblasts that can give rise to both blood and endothelium (Murray 1932; Dzierzak
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and Speck 2008). However, their fate is restricted once they have emigrated into extraembryonic tissue (extra embryonic ectoderm, yolk sac and allantois) and intra-embryonic
tissues (embryonic ectoderm). In extra-embryonic tissue, these angioblasts aggregate to
form blood islands, which are basic endothelial lined structures that are perfused with
primitive erythrocytes (Sabin 1920). Fusion of blood islands leads to the formation of a
honeycomb-shaped primitive capillary plexus. However, in intra-embryonic tissue,
angioblasts aggregate to directly form vessels such as the dorsal aorta and cardinal
vein, without a vascular plexus intermediate (Coffin and Poole 1988) (Figure 1.2).

After the primitive vascular plexus along with dorsal aorta and cardinal vein are
established, the vasculature undergoes growth and remodeling to form a mature
circulatory system. Much of the growth of blood vessels at this point is through the
process of angiogenesis, which again is the formation of new vessels from existing
vessels. There are two types of angiogenesis; sprouting angiogenesis and
intussusception (splitting) angiogenesis (Udan, Culver et al. 2013). Sprouting
angiogenesis begins with signals to induce the formation of new vessels. The most well
known inductive or pro-angiogenic signals are from the vascular endothelial growth
factor (Vegf) family of ligands (Neufeld, Cohen et al. 1999; Coultas, Chawengsaksophak
et al. 2005). Vessel induction is the first step in angiogenesis, and Vegf ligands along
with their receptors coordinate with multiple signaling pathways, NOTCH signaling in
particular, to induce, specify, grow, and fuse endothelial cells and vessels during
angiogenesis (Adams and Eichmann 2010).
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Concurrent with vasculogenesis and angiogenesis, endothelial cells and vessels begin to
specify and commit towards an arterial, venous, or lymphatic fate. This specification is
evidenced by the differential expression of marker genes or receptors on cells that are
fated to one lineage versus another (Herzog, Guttmann-Raviv et al. 2005). This is seen
in the exclusive expression of the receptor ephrin B2 on arterial endothelial cells and its
cognate receptor EPH receptor B4 (Ephb4) on venous endothelial cells (Wang, Chen et
al. 1998). These molecular markers are important tools in investigating vascular
development and identity, which I utilize in my studies in Chapter 4. The heterogeneity in
receptor makeup between arterial and venous endothelium can also help explain the
sensitivity of certain endothelial cells to specific signals, and the divergent patterning and
composition of these vessels even within close proximity.

While vasculogensis, angiogenesis, and specification explain how endothelial cells and
vessels come to be and grow, how the ultimate pattern of the vascular system is
determined is a different question. Like the patterning of the nervous system, the pattern
of the vascular system has been shown to guided by various signaling molecules
(Adams and Eichmann 2010). These signaling molecules can direct endothelial motility
and migration (Miao, Soker et al. 1999), remodel existing vessels through processes like
pruning (Serini, Valdembri et al. 2003), and are crucial to proper pattern formation (Gu,
Yoshida et al. 2005). My thesis work has been particularly interested in one such
molecule, Semaphorin 3d (Sema3d), and the associated receptors/signaling molecules,
which I will discuss later in this chapter and investigate in Chapters 2-4.
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Pulmonary Vein Development and Disease

As I will present and discuss in Chapter 2, my interest in congenital heart disease and
cardiovascular patterning began with a phenotype we found in mice null for Sema3d.
Mice lacking Sema3d develop abnormal connections of the pulmonary vein known as
anomalous pulmonary venous connection (APVC). Normally, the pulmonary veins carry
oxygenated blood from the lungs to the left atrium to be pumped to the left ventricle and
the rest of the body by way of the aorta. Peripheral tissues utilize this oxygenated blood
and deoxygenated blood is returned to the right atrium to be pumped back to the lungs
via the right ventricle and pulmonary artery. When the pulmonary veins fail to connect to
the left atrium and instead connect to the systemic circulatory system via the right atrium,
a condition arises known as Anomalous Pulmonary Venous Connection (APVC)(Brody
1942). APVCs can either be partial (PAPVC, some abnormal connections) or total
(TAPVC, all pulmonary veins) and is a serious condition that can lead to cyanosis, heart
failure, and death. Since fetal circulation bypasses the lungs until birth by the right-to-left
shunting through the foramen ovale and ductus arteriosus, TAPVC does not affect the
fetus until birth when they begin to use their lungs. As I introduced earlier, TAPVC is
classified in the cyanotic category of congenital heart defects and is one of the so called
“blue baby syndromes.” Interestingly, as many as 1 in 140 individuals have been
reported to have PAPVCs upon post-mortem examination (Healey 1952; Kalke, Carlson
et al. 1967). Although TAVPC is more rare, it is a much more serious condition with a
mortality rate as high as 80% if left untreated (Burroughs and Edwards 1960).
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Compared with our progressive understanding of the morphogenesis and molecular
pathways involved in patterning of the outflow tract, which I will discuss later in this
introductory chapter, very little is know about the molecular determinants and signals
regulating the development pulmonary vein. Much of the studies investigating the
development of the pulmonary veins have relied on descriptive anatomical analyses of
staged embryos from human, mouse, and chick (Auer 1948; DeRuiter, Gittenberger-De
Groot et al. 1995; Webb, Brown et al. 1998). Early pulmonary vein development is
actually fairly conserved between vertebrate species, with some differences evident at
later stages. For example, in the human, all four pulmonary veins have individual
connections to the back of the heart, whereas in mouse, the pulmonary veins converge
to form a common pulmonary vein before entering the left atrium (Sizarov, Lamers et al.).
These descriptive analyses, however, failed to answer even some of the most basic
questions about pulmonary vein development, namely where the pulmonary veins
originate, and how do APVCs come about? Until very recently, there were conflicting
hypotheses for these questions (Manner and Merkel 2007; Moorman and Anderson
2007). The question of origin was partially answered in 2011 using a combination of
high-resolution 3 dimensional imaging and molecular markers to determine cell identity
(van den Berg and Moorman 2011). It was found that the pulmonary veins develop from
a larger vascular plexus within the splanchnic mesoderm. Using our Sema3d null mice
as a model, we attempt to resolve the controversy around the etiology and
morphogenesis of TAPVC as I outline in Chapter 2.

Furthermore, very little was known about the molecular mechanisms involved in these
processes. What we did know was from familial genetic studies of TAPVC that have
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suggested an autosomal dominant inheritance of the disorder with incomplete
penetrance that maps to chromosome loci 4q12 (Bleyl, Ruttenberg et al. 1994; Bleyl,
Nelson et al. 1995; Bleyl, Botto et al. 2006). Further analysis refined the location to an
intergenic region between the gene for platelet-derived growth factor alpha (PDGFRA)
and KIT. Blocking of Pdgfra by the receptor tyrosine kinase (RTK) inhibitor Imatinib
(Buchdunger, Cioffi et al. 2000; Buchdunger, O'Reilly et al. 2002) in developing chick
embryos resulted in TAPVC at a frequency of 25% (Bleyl, Saijoh et al. 2010). The same
group examined the developing pulmonary veins of global Pdgfra knockout mice as well
in temporally (E7.5) and spatially (dorsal mesocardium) restricted conditional knockouts.
In all cases TAPVC was observed, albeit at a very low frequency. TAPVC is also
associated with ANKRD1 gene overexpression. This is based on a chromosomal
translocation or on a mutation in a putative PEST degradation motif in affected
individuals (Cinquetti, Badi et al. 2008).

While investigating the molecular mechanism by which Sema3d signaling patterns the
pulmonary veins, the genetic evidence linking PDGFRA and TAPVC suggested shared
pathways. As I will expand on later in this introduction, Sema3d is a secreted ligand and
PDGFRA is a receptor tyrosine kinase. I hypothesized that PDGFRA may be a signaling
receptor for Sema3d and sought to test that hypothesis, presented in Chapter 5, which
turned out not to be the case. As happens frequently in science, my experimentation led
me in an interesting new direction. I found that vascular inactivation of the Pdgfra gene
led to a different cyanotic congenital heart defect, namely transposition of the great
arteries (TGA), which I discuss in the next section.
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Outflow Tract Development and Disease
	
  
The cardiac outflow tract (OFT) is the embryonic precursor to the great arteries, namely
the ascending aorta and the pulmonary artery. In the embryo the OFT encompasses the
arterial pole of the heart and connects the nascent ventricles of the heart with the aortic
sac, a precursor to the ascending aorta and some pharyngeal arch arteries. A complex
process of remodeling occurs to the outflow tract during development (Figure 1.1). The
outflow tract starts off as a single endothelial lined myocardial tube, known as the
truncus arteriosus, that will rotate and septate concurrent with the septation of the
ventricles to ultimately give rise to a discrete aorta connecting to the left atrium and
pulmonary artery connecting with the right atrium (Sugishita, Watanabe et al. 2004). Any
perturbations to this process that lead to abnormal development results in a set of
congenital heart defects known as conotruncal anomalies. Conotruncal anomalies
include persistent truncus arteriosus (PTA) where the outflow tract fails to septate,
double outlet right ventricle (DORV) where both the aorta and pulmonary artery arise
from the right ventricle, Tetralogy of Fallot (ToF) which is a constellation of abnormalities,
and transposition of the great arteries (TGA) in which the aorta incorrectly connects to
the right ventricle and the pulmonary artery incorrectly connects to the left ventricle. All
together, conotruncal anomalies account a significant portion of all congenital heart
defects.

Crucial to OFT development is the formation of the endocardial cushions populated by
endothelial cells undergoing epithelial to mesenchymal transition (EMT) and migrating
into the cardiac jelly, and invading cardiac neural crest cells migrating from the dorsal
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neural tube through the pharyngeal arches (Sugishita, Watanabe et al. 2004). Ablation of
cardiac neural results in various conotruncal defects (Kirby and Waldo 1995).
Interestingly, transposition of the great arteries, which I discuss in the next section, is not
one of the defects observed after neural crest ablation.

Transposition of the Great Arteries (TGA)
	
  
Unlike our progressive understanding of the genetic, cellular, molecular, and
morphologic processes of various conotruncal anomalies such as PTA, DORV, and ToF,
very little is known of the etiology and morphogenesis of TGA (Unolt, Putotto et al.
2013). There are a few genes that have been associated with this CHD in human
(Goldmuntz, Bamford et al. 2002; Muncke, Jung et al. 2003; Karkera, Lee et al. 2007).
Our lack of understanding of TGA is compounded by a paucity of animal models of this
disorder. Currently there is only one descriptive study of TGA arising in mice null for the
vascular extracellular matrix (ECM) molecule Perlecan (Costell, Carmona et al. 2002).
Unfortunately, the only clue this study offers to the understanding of TGA is the presence
of hyperplastic endocardial cushions. In Chapter 5, I describe a new animal model for
TGA from endothelial inactivation of Pdgfra, and present additional clues to help
decipher the morphogenesis and etiology of TGA.

Coronary Vasculature Patterning

A group of abnormalities related to congenital heart defects are congenital abnormalities
of the coronary vessels. The coronary vessels serve to provide oxygen and nutrients to
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the myocardium (heart muscle) and return deoxygenated blood and waste products back
to the circulation. Early in mammalian development, simple diffusion is enough to
provide for the thin myocardium, but as the heart grows and thickens, the coronary
vasculature must develop to compensate. Failure of the coronary vasculature to properly
develop can have severe consequences including death (Angelini 2007).

Like the systemic circulation, coronary vessels are divided between arterial and venous.
Coronary arteries receive oxygenated blood from the aorta and deliver it to the heart
through smaller vessels and capillaries, and coronary veins return the blood to the
pulmonary circulation via the coronary sinus, which feeds into the right atrium. The
origins and development of the coronary vasculature are only now becoming apparent.
Up until the late 1980s, the prevailing understanding of coronary vasculature
development was that it came to be through the process of angiogenesis by sprouting off
of larger vessels; the aorta for the coronary arteries, and the coronary sinus for the
coronary veins (Hutchins, Kessler-Hanna et al. 1988). This notion was challenged when
the coronary vasculature was observed to be present before the connections to the
circulation were established (Bogers, Gittenberger-de Groot et al. 1989). Since that time
there has been some controversy regarding the origins of the coronary vasculature.
There is evidence for a number of sources for the endothelial cells that make up the
coronary vasculature including the proepicardium (Katz, Singh et al. 2012), epicardium,
endocardium, and sinus venosus (Red-Horse, Ueno et al. 2010; Chen, Sharma et al.
2014). Endothelial cells migrate from these sources to encompass the heart and come
together to form tube-like structures and a vascular plexus. Connections are formed
when the arterial vascular tubes around the aortic trunk penetrate the aorta, and the
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venous capillary beds form connections with the coronary sinus allowing for circulation of
blood through the coronary vessels.

The process by which the connections of the coronary vasculature to the circulation are
made is not entirely clear. There is, however, some evidence of the mechanisms
regulating coronary artery connections to the aorta. It has been shown that neural crest
ablation results in anomalous origins of the coronary arteries (Hood and Rosenquist
1992). Additionally, penetration of the coronary arteries into the aortic root requires Vegf
family ligands (Tomanek, Ishii et al. 2006). In Chapter 4 I will describe what I believe to
be the first evidence of the molecular mechanisms involved in coronary venous
connections.

Guidance Molecules in Cardiovascular Patterning

The common theme for much of my thesis work on congenital heart disease has been
elucidating the signals required for the vasculature to pattern correctly. Establishment
and growth of blood vessels build a framework, but this vascular framework requires
remodeling and guidance to form a functional vasculature. In this section I discuss the
various signaling molecules that I have found to be involved in vascular patterning and
congenital heart disease. These include ligands that signal to the developing
vasculature, receptors residing on endothelial cells to receive such signals, and
intermediate signaling molecules that transduce these signals.
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Semaphorins
	
  
Semaphorins are a large family of secreted or membrane associated glycoproteins that
are highly conserved both structurally and functionally throughout evolution from viruses
to mammalians. Semaphorins and neuropilin receptors were initially identified as axon
guidance molecules in the developing nervous system (Luo, Raible et al. 1993; He and
Tessier-Lavigne 1997). Subsequently, semaphorins have been shown to function in a
wide range of developmental, physiological and pathological processes outside of the
central nervous system including lymphocyte activation, neural crest cell migration,
vascular endothelial cell motility, bone growth, tumor angiogenesis and progression, lung
branching morphogenesis and cardiovascular development (Kruger, Aurandt et al. 2005;
Neufeld and Kessler 2008; Roth, Koncina et al. 2009; Neufeld, Sabag et al. 2012; Cora,
Astanina et al. 2014). My work has focused on the role of Semaphorins in vascular
patterning and congenital heart malformations (Table 1.1).

Semaphorin signals act by juxtacrine, paracrine and autocrine mechanisms to modulate
cellular behavior and are categorized into eight classes according to their structural
features and species of origin (Kruger, Aurandt et al. 2005). Class 1 and 2 semaphorins
are found in invertebrates, classes 3-7 are found in vertebrates and class 8 semaphorins
are encoded by viruses (Figure 1.3). Though semaphorins differ in their amino acid
sequence and overall structural characteristics, all members of the family contain a
conserved ~500 amino acid “sema” domain located near the amino terminus of the
mature protein. The sema domain is essential for receptor binding specificity and
signaling (He and Tessier-Lavigne 1997; Koppel, Feiner et al. 1997). The sema domains
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of several different semaphorins were recently characterized by mutagenesis, X-ray
crystallography and three-dimensional modeling, which reveals that the sema domain is
a variant of the seven blade β-propeller fold with overall structural similarities to the βpropeller repeats of α-integrins (Siebold and Jones 2013).

The different classes of semaphorins are characterized by class specific structural
motifs. For example, classes 2-4 and 7 contain a single copy of an immunoglobulin-like
domain, while class 5 semaphorins contain seven copies of a thrombospondin domain.
All vertebrate and invertebrate semaphorins contain a PSI (plexin-semaphorin-integrin)
domain that is required for homodimerization (Klostermann, Lohrum et al. 1998). Another
important feature that differs between different semaphorin classes is the presence of
membrane anchoring sequences. Classes 2 and 3 semaphorins are produced as
secreted proteins, whereas classes 1, 4, 5 and 6 are intrinsic membrane proteins and
class 7 semaphorins are membrane anchored proteins, which can be further processed
into soluble proteins by proteolytic cleavage (Figure 1.3) (Siebold and Jones 2013).

Class 3 Semaphorins

I have been particularly interested in the role of class 3 semaphorins in vascular
development. There is a growing body of literature implicating class 3 semaphorins in
modulating endothelial behavior. Sema3a signals through Nrp1 on endothelial cells to
inhibit proliferation, survival, migration, adhesion and capillary sprouting in aortic ring
assays and can modulate retinal neovascularization after injury as well as vascular
permeability (Miao, Soker et al. 1999; Acevedo, Barillas et al. 2008; Joyal, Sitaras et al.
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2011). However, whether knockout of Sema3a causes abnormalities of murine vascular
development remains controversial (Serini, Valdembri et al. 2003; Vieira, Schwarz et al.
2007). Sema3b repels endothelial cells by binding to Nrp1, therefore functioning as an
angiogenesis inhibitor (Varshavsky, Kessler et al. 2008). Sema3c induces endothelial
cell proliferation, adhesion and migration (Banu, Teichman et al. 2006). As I will show in
Chapter 3, Sema3d inhibits endothelial tube formation, adhesion, and motility through
Nrp1 and PI3K/Akt dependent pathways. Sema3f inhibits adhesion of endothelial cells
to fibronectin and FGF-induced human umbilical vein endothelial cell proliferation and
survival (Serini, Valdembri et al. 2003; Kessler, Shraga-Heled et al. 2004). Sema3g acts
as a positive regulator of angiogenesis by stimulating endothelial cells and activating
smooth muscle cells (Kutschera, Weber et al. 2011). In Chapter 3 I compare and
contrast the effects of two of these Semaphorins, Sema3d and Sema3e, on endothelial
cells.

Neuropilins

Two families of semaphorin receptors have been identified: plexins and neuropilins
(Figure 1.3 and Tables 1.1, 1.2). Most membrane bound semaphorins bind directly to
the plexin receptors. However this is generally not the case with (class 3) semaphorins,
with the exception of semaphorin 3e (Sema3e), which require an initial interaction with a
neuropilin co-receptor (Nrp1/Nrp2) to transduce their signal to plexin receptors (Gu,
Rodriguez et al. 2003). Neuropilins are promiscuous co-receptors regarding both ligands
and receptor partners that participate in a broad range of signaling pathways (Neufeld,
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Kessler et al. 2002; Gu, Rodriguez et al. 2003; Hillman, Feng et al. 2011; Muders 2011;
Rizzolio and Tamagnone 2011).

The role played by neuropilin receptors in the vasculature is complicated by the fact that
they can participate directly in Vegf signaling by heterodimerizing with Vegfr2 (Kdr)
(Soker, Takashima et al. 1998; Kawasaki, Kitsukawa et al. 1999; Lee, Goishi et al.
2002). Nrp1 knockout embryos display a wide range of vascular defects, and
overexpression of Nrp1 leads to excessive formation of blood vessels and capillaries
(Kitsukawa, Shimono et al. 1995). Nrp1 is strongly expressed on the newly formed
vasculature during wound healing and blocking of Nrp1 signaling reduces vascular
density within the wound (Matthies, Low et al. 2002). Nrp2 deficient mice are viable
(Chen, Bagri et al. 2000; Giger, Cloutier et al. 2000) but Vegf-induced retinal
neovascularization is significantly compromised in Nrp2-/- mice (Shen, Samul et al.
2004). Double Nrp1/Nrp2 knockout mice die as early as E8.5 and display a more severe
vasculature phenotype than single knockouts suggesting partial functional redundancy
(Takashima, Kitakaze et al. 2002).

Abnormalities of the outflow tract have been described in Nrp1 knockout (Kawasaki,
Kitsukawa et al. 1999) and endothelial-specific Nrp1 knockout mice (Gu, Rodriguez et al.
2003). However, PTA is not observed in mice expressing a form of neuropilin-1 unable to
bind class 3 semaphorins (Nrp1sema-) suggesting that sema-independent Nrp1 signaling
in endothelial cells is essential for OFT septation (Gu, Rodriguez et al. 2003).
Interestingly, Nrp1sema- mice on a Nrp2 null background do display PTA, suggesting
functional redundancy. Since Nrp1 can bind Vegf in addition to semaphorins, it is
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possible that Vegf-dependent Nrp1 signaling modulates OFT development accounting
for these findings. However, Gu et al. recently reported the phenotype of a Nrp1 mutant
mouse in which Nrp1 was mutated to specifically abolish Vegf binding. The resulting
Nrp1Vegf- mice survive to adulthood and do not display OFT defects (Gelfand, Hagan et
al. 2014). The relative influence of Vegf versus semaphorin signaling via neuropilins
remains to be fully elucidated.

Plexins

The plexins are a conserved family of large proteins (~200 kDa), initially identified as cell
surface molecules mediating cell adhesion (Ohta, Mizutani et al. 1995). Nine members
have been identified in vertebrates that are divided into four classes: class A (plexin A1,
A2, A3, A4), class B (plexin B1, B2, B3), class C (plexin C1) and class D (plexin D1)
(Tamagnone, Artigiani et al. 1999). Unlike semaphorins, plexin architecture is conserved
throughout the family. The extracellular domain of plexins contains one sema domain
followed by three PSI and three IPT (Ig-like, plexin and transcription factor) repeats
(Kruger, Aurandt et al. 2005). The sema domain acts as an autoinhibitory element
modulating plexin activation in addition to its role in binding ligand (Figure 1.3). For
example, plexin A1 (Plxna1) mutants lacking the sema domain are constitutively active
suggesting that the sema domain is necessary to maintain Plxna1 in its basal inactive
state (Takahashi and Strittmatter 2001). The IPT domain plays an important role in
protein-protein interaction (Watarai, Sekine et al. 2008).
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In Chapter 3 I investigate plexin D1 (Plxnd1) as a possible receptor for Sema3d. Plxnd1
is expressed by endothelial cells during cardiovascular development (Gitler, Lu et al.
2004; Zhang, Singh et al. 2009). Plxnd1 null pups and endothelial-specific Plxnd1
knockouts die shortly after birth due with PTA, defective aortic arch arteries and
ventricular septal defects (Gitler, Lu et al. 2004; Zhang, Singh et al. 2009). Mutations of
PLXND1 have been associated with isolated cases of truncus arteriosus in humans (TaShma, Pierri et al. 2013). Recent work by Worzfeld et al. demonstrates that transgenic
mice harboring mutations in the GAP domain of Plxnd1 recapitulate the phenotype of
Plxnd1 null mice suggesting that the GAP domain is essential for Plxnd1 signaling during
cardiac development (Worzfeld, Swiercz et al. 2014). Plxnd1 may interact with Nrp1 to
transduce a Sema3c signal (Toyofuku, Yoshida et al. 2008) but the spectrum of Plxnd1
ligands has yet to be fully defined, and the mechanism by which loss of Plxnd1 signaling
in endothelium results in OFT defects remains obscure.

ErbB Receptors

Receptor tyrosine kinases (RTKs) are a group of single pass transmembrane
glycoproteins that are involved in numerous biological processes including cell
proliferation, differentiation, survival, death, and migration. RTKs consist of an
extracellular ligand binding domain and an intracellular kinase domain. Binding of ligands
to RTKs can transduce extracellular signals to a cell through the homo- or heterodimerization of said receptors resulting in intracellular signaling. One such group of
RTKs of particular interest to us is the epidermal growth factor receptor family also
known as the ErbB family. The ErbB family of RTKs consist of four receptors; epidermal
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growth factor receptor (EGFR/ErbB1/HER1), erb-b2 receptor tyrosine kinase 2 (ErbB2,
HER2, neu), erb-b2 receptor tyrosine kinase 3 (ErbB3, HER3), and erb-b2 receptor
tyrosine kinase 4 (ErbB4, HER4)(Riese and Stern 1998). The primary ligands for ErbB
receptors are the EGF family of growth factors which include epidermal growth factor
(EGF) and neuregulins 1 through 4 (NRG1-4), as well as transforming growth factor
alpha (TGFA), amphiregulin (AR), heparin-binding EGF-like growth factor (HB-EGF),
tomoregulin, epiregulin, epigen, betacellulin, and neuroglycan C (Massague and
Pandiella 1993). These ligands have differential binding specificity to ErbB receptors. For
example, EGF, TGFA, and AR preferentially bind to EGFR, whereas NRG1 and NRG2
bind to ErbB3 and ErbB4. ErbB2 is the exception to this family as it has no direct ligand,
but rather acts as the preferential co-receptor for the other ErbB receptors. This is
evident in the ligand-induced interaction of ErbB2 and ErbB3. ErbB3 is unique in that it
does not possess kinase activity, and ligand binding to ErbB3 can induce
heterodimerization with ErbB2 and subsequent kinase activation of ErbB2 (Kim,
Vijapurkar et al. 1998). The receptor ErbB2, also known as HER2, is best known for its
role in cancer. ErbB2 is overexpressed in a subset of cancers, particularly breast
cancers, that usually have a more aggressive progression (Yu and Hung 2000).
However, ErbB2 has been successfully targeted in these cancers with a specific
monoclonal antibody to ErbB2, trastuzumab, which has led to overall better outcomes.

ErbB receptors have been shown to be important in development. Deletion of these
genes results in various phenotype including cardiovascular ones. Global deletion of
ErbB2 or ErbB4 in mice results in embryonic lethality around E10.5 from defects in
cardiac trabeculation and nervous system development (Lee, Simon et al. 1995; Meyer
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and Birchmeier 1995). Mice deficient in ErbB3 have defective valve formation (Erickson,
O'Shea et al. 1997). And mice lacking EGFR have a range of phenotypes dependent on
background and strain, from preimplantation lethality to valve malformations (Miettinen,
Berger et al. 1995; Sibilia and Wagner 1995; Threadgill, Dlugosz et al. 1995; Chen,
Bronson et al. 2000). Targeted studies examining the effects of ErbB2 loss in
cardiomyocytes result in a phenotype of dilated cardiomyopathy (Crone, Zhao et al.
2002; Ozcelik, Erdmann et al. 2002). More recently, ErbB2 has been shown to be critical
in cardiomyocyte proliferation and regeneration and this pathway has become an
attractive target for cardiac regenerative therapies (D'Uva, Aharonov et al. 2015). While
the role of ErbB2 in cardiomycotes has been extensively studied, in Chapter 4 I explore
an as of yet unappreciated aspect of the role ErbB2 during development. Specifically, I
have found that ErbB2 is expressed in vascular endothelium during development and
plays a critical role in coronary patterning.

Pdgf Receptors

Platelet derived growth factor receptors (Pdgfr) are receptor tyrosine kinases for the
platelet derived growth factor (Pdgf) family of ligands. There are 2 Pdgfr molecules
encoded by distinct genes, Pdgfr-alpha (Pdgfra) and Pdgfr-beta (Pdgfrb). Like the ErbB
receptors, Pdgf receptors require dimerization to signal, which is dependent on ligand
specificity. We became interested in Pdgfra because of evidence, discussed earlier in
this introduction, suggesting an association with TAPVC.
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Pdgfra is expressed in many cells of the heart including the multipotent cardiac
progenitor cells during development (Van Den Akker, Lie-Venema et al. 2005; Bax, LieVenema et al. 2009; Chong, Reinecke et al. 2013; Noseda, Harada et al. 2015). Global
mutation of Pdgfra results in various cardiovascular malformations such as persistent
truncus arteriosus, and double outlet right ventricle (Schatteman, Motley et al. 1995).
These conotruncal abnormalities have been attributed to the role of Pdgfra in the neural
crest (Richarte, Mead et al. 2007). Pdgf receptors have been investigated in multiple cell
type important in heart development including cardiomyocytes (French, Creemers et al.
2008), smooth muscle (French, Creemers et al. 2008), cardiac neural crest (Smith and
Tallquist 2010), and epicardial cells. Surprisingly, very little is known about Pdgfra
expression or function in endothelial cells. As I will show in Chapter 5, we find that
Pdgfra is expressed in the embryonic vasculature, and conditional deletion of Pdgfra in
endothelium leads to an entirely new phenotype not previously reported of transposition
of the great arteries.

Conclusions

In this introductory chapter I have described how the heart and vasculature normally
develop, and what we know about what happens when things go wrong. In the following
chapters I use mouse genetic tools to further shed light on the etiology and
morphogenesis of the congenital defects I discussed in this chapter. I will also
demonstrate the interaction of many of the signaling pathways included in this chapter,
and how these convergent signaling pathways are involved in cardiovascular patterning.
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Table 1.1
Mutation(s)

Receptors
or
Ligands
Semaphorins
-/Sema3a
Plexin A1A4, D1,
Nrp1-2,
Vegfr2

Sema3b

Sema3c

-/-

Cardiovascular phenotypes
and functions

Refs.

Postnatal

Atrial defects, sinus
bradycardia,
lymphatic valve defects,
vascular patterning defects.
Sema3a inhibits
angiogenesis.

Plexin A1A4, Nrp1-2,
Vegfr2
Plexin A2,
D1, Nrp1-2

Viable

No obvious cardiac defects.
Sema3b inhibits
angiogenesis.
PTA, VSD, aortic arch
defects. Sema3c promotes
angiogenesis.

(Ieda, Kanazawa et
al. 2007; Bouvree,
Brunet et al. 2012;
Jurisic, Maby-El
Hajjami et al. 2012;
Chen, Li et al.
2013)
(Falk, Bechara et
al. 2005)

Postnatal
(varies
with
strain)

Sema3d

-/-

Nrp1

Viable

Sema3e

-/-

Plexin As
(neuropilin
dependent),
Plexin D1

Viable

Plexin A3,
A4, Nrp1-2

Viable

Sema3f

	
  
	
  

-/-

Stage of
lethality

-/-

Sema3g

-/-

Nrp1-2

Viable

Sema4a

-/-

Plexin B1-3,
Plexin D1,
Met, Erbb2

Viable

Sema4d

-/-

Plexin B1-2,
C1, Met,
Erbb2

Viable

Anomalous pulmonary
venous connection, ASD.
Sema3d repels pulmonary
vein endothelial cells.
Vascular patterning defects.
Sema3e restricts blood
vessel growth to the
intersomitic boundaries.
Inhibits angiogenesis. A 61kDa Sema3e isoform
promotes endothelial cell
migration.
No obvious phenotype.
Sema3f inhibits angiogenesis
and lymphangiogenesis.
Vascular remodeling defects.
Sema3g promote
angiogenesis.
Enhanced angiogenesis in
response to Vegf or
inflammatory stimuli. Sema4a
inhibits angiogenesis.
Delayed atherosclerotic
plaque formation due to
impaired neovascularization.
Sema4d promotes
angiogenesis.

	
  

23	
   	
  

(Feiner, Webber et
al. 2001)

(Katz, Singh et al.
2012; Degenhardt,
Singh et al. 2013)
(Gu, Yoshida et al.
2005; Casazza,
Finisguerra et al.
2010)

(Sahay, Molliver et
al. 2003)
(Kutschera, Weber
et al. 2011)
(Kumanogoh,
Shikina et al. 2005;
Toyofuku, Yabuki et
al. 2007)
(Zhu, Stalker et al.
2009; Yukawa,
Tanaka et al. 2010)

	
  

	
  
	
  

Sema5a

-/-

Plexin A3,
B3, Nrp2,
Met, Erbb2

Viable or
embryonic

Defective cranial blood vessel
remodeling. Sema5a
promotes angiogenesis.

Sema6a

-/-

Plexin A1,
A2, A4,
Vegfr2

Viable

Sema6d

-/-

Plexin A1

Viable

Abnormal retinal vascular
development. Sema6a
promotes angiogenesis. A
soluble form of Sema6a
inhibits angiogenesis.
No obvious phenotype in
mice. Sema6d modulates
compact layer expansion and
trabeculation in chick.

	
  

24	
   	
  

(Fiore, Rahim et al.
2005; Matsuoka,
Chivatakarn et al.
2011)
(Segarra, Ohnuki et
al. 2012)

(Toyofuku, Zhang
et al. 2004;
Toyofuku, Zhang et
al. 2004;
Takamatsu,
Takegahara et al.
2010)

	
  

Table 1.2
Mutation(s)
Plexins
-/Plxna1

Receptors or
Ligands

Stage of
lethality

Cardiovascular phenotypes and
functions

Refs.

Sema3a,
Sema5a or
5b, Sema6c
or 6d

Viable

No obvious cardiac defects.
Lymphatic valves are abnormal.

PTA and lack of aortic and
pulmonary channel septation with
incomplete penetrance. Double
knockouts lacking Plxna2 and
Plxna4 exhibit cardiovascular
defects with higher penetrance.
Double knockouts lacking Plxna2
and Plxna4 exhibit cardiovascular
defects with higher penetrance.
PTA, VSD, atrial defects,
coronary artery and aortic arch
defects.

(Takegahara,
Takamatsu et
al. 2006;
Bouvree,
Brunet et al.
2012)
(Suto, Tsuboi
et al. 2007;
Toyofuku,
Yoshida et al.
2008)

Plxna2

-/-

Sema6a or
6b

Viable

Plxna4

-/-

Sema6a or
6b

Viable

-/-

Sema3a, 3c
(neuropilin
dependent)
Sema3e, 4a
(neuropilinindependent)

Postnatal

Plxnd1
and
ecKO
Plxnd1

Neuropilins
-/Nrp1
Coreceptor
for class 3
semaphorins
ecKO
Nrp1
and others
Nrp1

Nrp2

-Sema

Various cardiac and vascular
defects including PTA and aortic
arch defects.

Perinatal

PTA, BAE, AOC, VSD.

Postnatal

BAE, VSD, lymphatic vessels and
valve defects.
Lymphatic vessel and capillary
formation defect.

-/-

Coreceptor
for class 3
semaphorins
and others

Viable

-/-

Coreceptor
for class 3
semaphorins
and others
Coreceptor
for class 3
semaphorins
and others

Embryonic
(~E8.0)

Vascular anomalies in both
embryos and placenta.

Not
reported

PTA, BAE, AOC and VSD, no
vascular defects reported.

Nrp1 ;
-/Nrp2

Sema-

Nrp1
-/Nrp2

	
  
	
  

Embryonic
E10.512.5

;
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(Toyofuku,
Yoshida et al.
2008)
(Gitler, Lu et
al. 2004;
Zhang, Singh
et al. 2009)

(Kawasaki,
Kitsukawa et
al. 1999; Gu,
Rodriguez et
al. 2003)

(Giger,
Cloutier et al.
2000; Yuan,
Moyon et al.
2002)
(Takashima,
Kitakaze et al.
2002)
(Gu,
Rodriguez et
al. 2003)

	
  

Figure 1.1 Cardiac development
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Figure 1.1 Cardiac development
The heart originates from mesodermal cells in the primitive streak. During gastrulation,
cardiac progenitors migrate to the splanchnic mesoderm to form the cardiac crescent. At
E7.5 in the mouse, the cardiac crescent can be divided into two heart field lineages
based on differential gene expression and their respective contribution to heart, a first
heart field (red) and a second heart field (yellow), which is located posteriorly and
medially to the first heart field. At E8.0, the linear heart tube is present. At E8.5, the
looping is associated with uneven growth of cardiac chambers. The outflow tract is at
the arterial pole and the inflow tract and primitive atria are at the venous pole. By E9.5,
the common atrium has moved superior to the ventricles and is separated by a distinct
atrio-ventricular canal. By E10.5, cardiac neural crest cells from the dorsal neural tube
migrate via the pharyngeal arches to the cardiac outflow tract. Further cardiac
development involves a series of septation events and myocardial trabeculation that
result in a mature four-chambered heart integrated with the circulatory system depicted
at E15.5. Figure from (Epstein, Aghajanian et al. 2015).
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Figure 1.2 Schematic overview of mammalian vascular development
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Figure 1.2 Schematic overview of mammalian vascular development.
Vascular endothelial progenitor cells, known as angioblasts, are derived during
gastrulation from mesodermal cells. These mesodermal cells have potential to give rise
to both blood and endothelium. However, once they have emigrated into extra-embryonic
tissue (extra embryonic ectoderm, yolk sac and allantois) and intra-embryonic tissues
(embryonic ectoderm) their fate becomes restricted. These angioblasts aggregate to
form blood islands in extra-embryonic tissue. Blood islands fuse to form a honeycombshaped primitive capillary plexus. In intra-embryonic tissue, angioblasts aggregate and
directly form the dorsal aorta and cardinal vein, without a vascular plexus intermediate.
The primitive vascular plexus along with dorsal aorta and cardinal vein undergo
remodeling to form a mature circulatory system. Lymphatic endothelial cells (LECs) are
specified in embryonic cardinal veins at defined locations. Figure from (Epstein,
Aghajanian et al. 2015).
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Figure 1.3 Structure of semaphorins and their receptors
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Figure 1.3
Semaphorins are categorized into eight classes based on their structural features and
species origin. Semaphorins are defined by the presence of a conserved “sema” domain
near the N-terminus of the protein. Class 1 and 2 semaphorins are found in
invertebrates, Class 3–7 in vertebrates and SemaV in certain viruses. Semaphorins are
secreted (Sema2a-2b, Sema3a-3g and SemaV), membrane-bound (Sema-1a,1b,
Sema4a-4g, Sema5a-5b and Sema6a-6d) or GPI-anchored proteins (Sema7a). Two
distinct transmembrane receptor families have been identified as semaphorin receptors,
plexins and neuropilins. Shown here are the eleven members of the plexin family,
including the invertebrate plexins (Plexin A and Plexin B), and the two members of the
neuropilin family. Generally, membrane-bound semaphorins (class 4–7) directly bind to
plexins. However, most secreted semaphorins (class 3) require neuropilins (Nrp1 and
Nrp2) as binding co-receptors to enable binding to plexins. Neuropilins provide binding
specificity for the class 3 semaphorins, whereas plexins, which also contain a sema
domain, serve as signaling partners. An exception to this rule is Sema3e; a secreted
semaphorin that can directly binds to plexinD1. Sema7a, a GPI-anchored semaphorin,
signals through integrin receptors. Vegfr2 can form a receptor complex with plexin A1
that is required for Sema6d-mediated signaling in cardiac development. Class 4 and 5
semaphorins are associated with plexin B1-3 receptors, and the receptor tyrosine
kinases Met and Erbb2 can function as coreceptors with plexin Bs for certain class 4
semaphorins. Protein domains are indicated: GAP, GTPase-activating protein; Ig-like,
immunoglobulin like; PSI, plexin semaphorin integrin; IPT, Ig-like plexin transcription
factors; CUB, complement C1r/C1s, Uegf, Bmp1; FV/VIII, coagulation factor V/VIII
homology like; MAM, meprin like. Figure from (Epstein, Aghajanian et al. 2015).
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Chapter 2 : Semaphorin 3d patterns the pulmonary veins
My interest in the signaling molecules responsible for patterning the vasculature began while
investigating the phenotype of the Sema3d null mice presented in this chapter. This work was
done in collaboration with two postdoctoral fellows in our lab, Karl Degenhardt and Manvendra
Singh. Much of this chapter was published as a letter in Nature Medicine (Degenhardt et al.,
2013) of which I was co-first author and contributed to almost all aspects of the project, including
the writing and revisions.

Summary
	
  
Total anomalous pulmonary venous connection (TAPVC) is a potentially lethal
congenital disorder that occurs when the pulmonary veins fail to connect normally to the
left atrium, allowing mixing of pulmonary and systemic blood (Brody 1942). In contrast to
the extensive knowledge of arterial vascular patterning, little is known about the
patterning of veins. Here we show that the secreted guidance molecule Semaphorin 3d
(Sema3d) is crucial for normal patterning of the pulmonary veins. Prevailing models
suggest that TAPVC occurs when the midpharyngeal endothelial strand (MES), the
precursor of the common pulmonary vein, fails to form at the proper location on the
dorsal surface of the embryonic common atrium (Lucas, Amplatz et al. 1962; Lucas,
Lock et al. 1988). However, analysis of Sema3d mutant embryos shows that TAPVC
occurs despite normal formation of the MES. Rather, the maturing pulmonary venous
plexus fails to anastomose uniquely with the properly formed MES, and forming
endothelial tubes penetrate a boundary normally produced by Sema3d, resulting in
aberrant connections. Sequencing of SEMA3D in individuals affected with anomalous
pulmonary veins identified a phenylalanine to leucine substitution that adversely affects
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Sema3d function. These results identify Sema3d as a critical pulmonary venous
patterning cue and provide experimental evidence for an alternate developmental model
to explain abnormal pulmonary venous connections.
Introduction

Complete separation of systemic and pulmonary circulations occurs shortly after birth in
humans. In adults, the right ventricle pumps blood through the pulmonary arteries to the
lungs, and oxygenated blood returns to the left atrium via the pulmonary veins. The left
ventricle pumps blood to the systemic circulation where oxygen is utilized by peripheral
tissues, and de-oxygenated blood is returned via the systemic veins to the right atrium.
When some or all of the pulmonary veins improperly connect to the right atrium or to the
systemic venous system, the clinical entities of partial anomalous venous connection
(PAPVC) or total anomalous venous connection (TAPVC) result, respectively (Brody
1942; Lucas, Lock et al. 1988; Seale, Uemura et al. 2010). The result is a left-to-right
shunt, with potential for cyanosis, increased volume load on the right heart, and heart
failure. PAPVC has been reported in up to one in 140 individuals (0.7%)(Adachi 1933;
Hughes and Rumore 1944; Healey 1952; Kalke, Carlson et al. 1967). TAPVC is less
common, but can result in severe cyanosis or congestive heart failure in infants. Left
untreated, the mortality of TAPVC is 80% (Burroughs and Edwards 1960).

In contrast to our progress in understanding the morphogenesis of the cardiac outflow
tracts and great arteries, little is known about the molecular regulation of pulmonary vein
formation. Early development of the pulmonary veins is similar among vertebrate
species including humans (Auer 1948). Subtle differences are evident at later stages.
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For example, in humans the pulmonary vein is incorporated into the back wall of the left
atrium and subsequent remodeling leaves four separate orifices (Sizarov, Lamers et al.),
while mice have a single common pulmonary vein that enters the left atrium. Descriptive
anatomic studies have suggested that pulmonary veins form initially as a dorsal
evagination from the posterior wall of the embryonic atrium (Auer 1948) leading
researchers to speculate that abnormal venous connections arise from absent or mislocalized evaginations (Lucas, Amplatz et al. 1962; Lucas, Lock et al. 1988). These
studies have supported the teaching that TAPVC is caused primarily by defects in
formation or maintenance of the midpharyngeal endothelial strand, the anlage of the
pulmonary veins (DeRuiter, Gittenberger-De Groot et al. 1995; Keane, Lock et al. 2006;
Moss and Allen 2008; Douglas, Jongbloed et al. 2010). Recently, use of high resolution
3D reconstructions of avian embryos has helped to clarify that the pulmonary vein
derives from a greater vascular plexus within the splanchnic mesoderm (van den Berg
and Moorman 2011). Incomplete remodeling of this plexus with failure of separation into
distinct pulmonary and systemic vascular zones has been postulated to be a
developmental mechanism that could result in APVC (van den Berg and Moorman
2011).

Human genetic studies of kindreds with TAPVC have provided evidence for autosomal
dominant inheritance with incomplete penetrance and variable expression (Bleyl, Nelson
et al. 1995; Bleyl, Botto et al. 2006), and genetic association has implicated loci on
human 4q12 (Bleyl, Botto et al. 2006). Candidate genes in that region include the
vascular endothelial growth factor receptor gene KDR (kinase insert domain receptor)
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and the gene encoding platelet derived growth factor receptor alpha (PDGFRA). Indeed,
a spectrum of inflow tract defects including a low incidence of TAPVC was noted in mice
after inactivation of Pdgfra either globally or in dorsal mesocardium (Bleyl, Saijoh et al.
2010). Overexpression of the ANKRD1 gene is also associated with TAPVC based on a
chromosomal translocation in one case or on a mutation in a putative PEST degradation
motif (Cinquetti, Badi et al. 2008). The molecular mechanisms by which perturbations in
these genes lead to anomalous connection of the pulmonary veins has yet to be
described.

Class 3 semaphorins are secreted molecules that primarily signal through neuropilin
and/or plexin coreceptor complexes. Semaphorins were originally identified as axon
guidance molecules, but have since been implicated in multiple biological processes
including cardiovascular patterning (Kruger, Aurandt et al. 2005; Kigel, Varshavsky et al.
2008; Larrivee, Freitas et al. 2009). For example, Semaphorin3e is required for
intersomitic artery patterning (Gu, Yoshida et al. 2005) and Semaphorin3c is required for
morphogenesis of the great arteries at the arterial pole of the heart (Feiner, Webber et
al. 2001). Sema3d is a related member of this class, that has been previously implicated
in retinal ganglion cell axon patterning, and neural crest migration in zebrafish (Berndt
and Halloran 2006; Sato, Tsai et al. 2006).
Results

To determine the role of Sema3d in cardiovascular development, we inactivated the
gene by homologous recombination in embryonic stem cells (Figure 2.1 and (Katz,
Singh et al. 2012)). We created two distinct alleles, one of which resulted in truncation of
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the protein after the 7th amino acid, and the other resulted in insertion of the coding
sequence for a fusion of green fluorescent protein (GFP) and Cre recombinase at the
initiating ATG. In the latter case, GFP expression accurately recapitulates endogenous
Sema3d expression (Katz, Singh et al. 2012). The resulting phenotype of both modified
alleles was identical. Heterozygous mice appeared normal, while homozygous deficient
animals exhibited abnormalities of pulmonary venous patterning. Affected Sema3d–/–
adult mice exhibited massively enlarged right atria and ventricles (Figure 2.2) consistent
with a left-to-right shunt. In control animals, the pulmonary veins were observed to
connect to the left atrium, as expected (Figure 2.2a,c,e,f). Anomalous connections to
the coronary sinus (which connects to the right atrium), or directly to the right atrium,
were noted in mutants (Figure 2.2b,d,g,h, Figure 2.3). Total or partial APVC was noted
in 35% (14/36) of homozygous mutants. The majority of affected animals displayed
TAPVC (13/14). TAPVC was associated with atrial septal defects in all of the affected
Sema3d mutants. However, we did not notice any other structural defects and no
abnormalities of laterality were observed in mutants.

In order to determine when patterning defects were first evident, we examined
Sema3d–/– murine embryos at progressively earlier stages. At E17.5, optical projection
tomography (OPT) imaging (Figure 2.4a,b) identified examples of abnormal connections
of the pulmonary vein to the coronary sinus (3/8 mutants) (Figure 2.4b). At E12.5
(Figure 2.4c,d), abnormal pulmonary venous connections were also identified in
Sema3d mutants (4/11 mutants) (Figure 2.4d). Staining for expression of the
endothelial marker Pecam1 (platelet and endothelial specific cell adhesion molecule) at
E10.5 (Figure 2.4e,f) revealed the first signs of abnormalities of vascular patterning in
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the region of the nascent pulmonary veins in mutants (4/10 mutants), which suggested
the formation of abnormal venous connections in ectopic locations (Figure 2.4f). At
E9.5, abnormalities in endothelial patterning were not observed (Figure 2.4g,h and
Figure 2.5). Importantly, the midpharyngeal endothelial strand (labeled in Figure 2.4g,h
and Figure 2.5) is easily identifiable at E9.5, and is unperturbed in Sema3d–/– embryos
(0/9 mutants) (Figure 2.4g,h and Figure 2.5). This contradicts the widely held belief that
failure of the formation of the normal pulmonary vein at the site of entry to the common
atrium is the primary defect leading to TAPVC (2008; Moss and Allen 2008). Rather, our
findings suggest that patterning and connections of the pulmonary portion of the
splanchnic venous plexus may be disrupted (see below).

Class 3 semaphorins signal through receptor complexes containing Neuropilins (Zhou,
Gunput et al. 2008). We examined Sema3d expression as marked by GFP
immunofluorescence in Sema3dGFPcre/+ mice, and Neuropilin-1 (Nrp-1) expression by
immunofluorescence (Figure 2.6). At E10.5, when patterning defects were first
observed, Sema3d is expressed in the mesocardial reflections that form an anatomic
boundary between the splanchnic mesoderm and the venous pole of the heart (Figure
2.6a–c,h,i). Nrp-1 is expressed by the midpharyngeal endothelial strand at E9.5 and by
pulmonary endothelial cells during early pulmonary vein patterning (Figure 2.6d, e and
Figure 2.7). Nrp-1 has been reported to be arterial specific in chick (Herzog, GuttmannRaviv et al. 2005), though not in other systems (Evans, Yamaji et al. 2011; Pellet-Many,
Frankel et al. 2011). We performed co-immunofluorescence for Nrp-1 and Eph receptor
B4 (Ephb4), a marker of venous endothelium. Nrp-1 and Ephb4 are co-expressed on
pulmonary venous endothelium (Figure 2.6e,f).
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To determine if Sema3d binds to pulmonary vein endothelium in vivo, we incubated
cryosections from wildtype E10.5 embryos with conditioned media from HEK293T cells
expressing alkaline-phosphatase tagged Sema3d (Sema3d-AP). Sema3d-AP binding
was detected in the region of the nascent pulmonary veins (Figure 2.6g). No AP binding
was detected on sections treated with control conditioned media (data not shown). The
pulmonary venous plexus is normally constrained entirely to the region medial to the
Sema3d expression domain and anastomoses with the midpharyngeal endothelial strand
(Figure 2.6h). However, in Sema3d mutants, numerous Pecam1 positive endothelial
cells and tubes penetrate the lateral and caudal boundaries and intermingle with cells
that would normally have been expressing Sema3d (identified by GFP
immunohistochemistry in mutant specimens) (arrows in Figure 2.6i). Quantification of
serial confocal stacks confirms significantly greater overlap of GFP and Pecam1
expression in mutants compared to controls (Figure 2.6j). The absence of Sema3d did
not affect pulmonary endothelial cell proliferation or survival (Figure 2.8), and thus our
data suggest that Sema3d regulates pulmonary vein patterning by directing pulmonary
endothelial cell localization.

Prior work has identified an avascular zone that forms within the splanchnic plexus to
separate the pulmonary venous plexus from more caudal vascular structures associated
with systemic veins (van den Berg and Moorman 2011). Interestingly, Sema3d is
expressed specifically within this avascular zone (Figure 2.9a–g) and this domain of
Sema3d expression appears inappropriately vascularized in Sema3d mutants (Figure
2.9h–k). These findings are consistent with the hypothesis that failure of formation of
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this avascular region could result in abnormal connections, as previously postulated (van
den Berg and Moorman 2011).

We sequenced the exons of SEMA3D in forty affected individuals (19 probands with
TAPVC and 21 probands with PAPVC) and identified several variants (Table 2.1). While
one of these variants, a c.193T>C missense which results in a serine to proline
substitution (p.S65P), was found in both affected and control populations at
approximately equal frequencies (1/20), a second c.1806T>A variant resulting in a
phenylalanine to leucine substitution of amino acid 602 (p.F602L) was found only in an
APVC affected individual and not in 80 control samples (Table 2.1 and Figure 2.10).
The affected individual was Caucasian (as were 78 of 80 controls), had PAPVC with an
associated VSD and had no evidence of laterality defects. Parental DNA was not
available. This p.F602L variant is predicted to be possibly damaging by PolyPhen in
silico analysis (Table 2.1), and the amino acid alteration is located in the
Immunoglobulin (Ig)-like domain of Sema3d which has been shown to be important for
both receptor binding and functional activity (Koppel, Feiner et al. 1997; Renzi, Feiner et
al. 1999). Additionally, the p.F602L variant is absent from the 1000 genomes data set
(1092 individuals) and the NHLBI Exome Sequencing Project (ESP) (13,000
chromosomes) (Fu, O'Connor et al.) and was not found among the >800 chromosomes
reported previously in which SEMA3D exons were sequenced for other reasons (Jiang,
Turner et al. 2012; Luzon-Toro, Fernandez et al. 2013).

In order to test the ability of wild type and variant Sema3d to bind to neuropilin receptors
and to mediate guidance of endothelial cells, we generated alkaline phosphatase fusion
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proteins. Binding to transfected Cos7 cells expressing Nrp-1 or Neuropilin-2 (Nrp-2)
suggested that wild type and both Sema3d variants that we tested could bind to Nrp-1,
although p.F602L bound with less affinity (Figure 2.11a and Figure 2.12). No significant
binding to Nrp-2 was detected. Wild type Sema3d-AP was also found to bind to human
umbilical vein endothelial cells (HUVECs) (Figure 2.13), which normally express Nrp-1
(Evans, Yamaji et al. 2011; Pellet-Many, Frankel et al. 2011). This binding was
significantly diminished with siRNA-mediated knockdown of Nrp-1 (Figure 2.14).

To determine the endothelial guidance properties of Sema3d variants, HEK293 cells
overexpressing either Sema3d or its variants were co-cultured with human umbilical vein
endothelial cells (HUVECs). Time-lapse video analysis as well as micrograph
quantitation confirms that Sema3d acts as a migratory repulsive cue in culture (Kigel,
Varshavsky et al. 2008) (Figure 2.11b,c). Sema3d (p.S65P) repelled HUVECs similarly
to wild type protein (Figure 2.11b,c); however, Sema3d (p.F602L) displayed markedly
reduced repulsion activity (Figure 2.11b,c).

To investigate whether Sema3d repulsion is mediated by Nrp-1, we blocked Nrp-1
signaling by adding either soluble Nrp-1 or a Nrp-1-specific blocking antibody to the
culture medium. Both soluble Nrp-1 and Nrp-1-specific antibody significantly reduced
HUVEC repulsion in response to Sema3d (Figure 2.11d,e). Although both arterial and
venous endothelium express Nrp-1, recent studies have shown that cell responsiveness
to semaphorin signaling can be mediated by differential expression of co-receptors as
well as intracellular signaling factors acting downstream of receptors (Chauvet, Cohen et
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al. 2007; Riccomagno, Hurtado et al. 2012). For example, Semaphorin 3e acts as a
repellent signal on neurons expressing Plexin D1 but not Nrp-1, but acts as an attractive
cue for neurons that express both (Chauvet, Cohen et al. 2007). Recently, Riccomagno
et al. have shown that the effects of Sema3f in the central nervous system can be
modulated by an intracellular Rac GTPase-activating protein, β2-chimaerin (β2Chn)
(Riccomagno, Hurtado et al. 2012). In the absence of β2Chn, Sema3f engagement of
Nrp-2 can mediate axon repulsion, but β2Chn is required for axon pruning in response to
Sema3f. Thus, the downstream effects of Sema-Nrp interaction may be dictated by the
expression or activities of receptors and downstream mediators.

Discussion

Taken together, these data implicate Sema3d as a repellent guidance molecule
functioning to pattern the forming pulmonary venous vasculature (Figure 2.11f). We
suggest that the absence of Sema3d-mediated repulsion allows pulmonary vasculature
to stochastically form anomalous connections to adjacent systemic venous structures
along a broad rostral-caudal domain, which could explain the morphologic APVC
variability in Sema3d mutants and the diverse types of anomalous connections found in
affected humans (van den Berg and Moorman 2011). The lack of repulsion leads to a
broad domain of abnormal endothelial sprouts, which may persist when they connect to
a systemic vein and receive significant blood flow. Hence, stochastic considerations
may contribute to variation in patterning. SEMA3D copy number variation has been
linked to congenital heart defects (Silversides, Lionel et al. 2012), and the functional
deficiencies of the p.F602L variant suggest a possible genetic contribution to this
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common form of congenital heart disease in children, although further studies will be
necessary to determine if SEMA3D mutations are sufficient to cause APVC in humans
and to what degree sequence variants may contribute to this phenotype. Genetic
variants or mutations in the genes involved in the Sema3d signaling cascade will be
important future targets of study in individuals with congenital heart disease and
pulmonary venous anomalies. Importantly, our data demonstrate a novel
pathophysiology of APVC development that challenges the long held dogma about the
etiology of this congenital disorder. Furthermore, these findings underscore the
existence of specific morphogenetic pathways affecting subtypes of the vasculature and
the importance of further investigation of the nature of vascular heterogeneity in
development and disease.

Materials and Methods

Generation of Sema3d mutant mice:
The generation and genotyping of Sema3dGFPcre knock-in mice are described elsewhere
(Katz, Singh et al. 2012). Sema3d+/- mice were made in a similar manner: ~20 kb of
mouse genomic sequence surrounding exon 2 of the Sema3d gene (chr5:1243810312457989 of NCBI37/mm9 assembly) was recombineered into the pL253 plasmid (Katz,
Singh et al. 2012). A FRTed PGKneo cassette was recombineered into exon 2 removing
the splice donor of exon 2. The recombineering also placed stop codons 18 bp
downstream of the ATG (Figure 2.1). Correctly targeted TL-1 ES cells were identified by
PCR. Primers used for screening were Sema3d-F: 5ʼATGACTGGGCACAACAGACAATCGG-3ʼ and Sema3d-R: 5ʼ	
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TGAGGATGGGAACTGGTGGTATCAG-3ʼ (Figure 2.1b). Targeting was also confirmed
by Southern blot (digest with EcoRV, probe with chr5:12,436,819-12,437,431, wild type
band ~22 kb, mutant band ~12 kb) (Figure 2.1c). After blastocyst injection, germline
transmission from chimeric males was confirmed by Southern and PCR as above, and
subsequent generations by PCR with the following- Forward primer: 5ʼATTGCATCGCATTGTCTGAG-3ʼ (F1). Reverse primer: 5ʼCTGCCACTGTCCTTCATTCC-3ʼ (R1). Sema3d-neo mice were crossed to beta-actin
FLPe mice (Jackson Labs) to remove the neomycin cassette generating Sema3d+/-.
Confirmation of FLPe excision of the cassette was performed by PCR. Forward primer:
5ʼ-GAATGTTACTAAAGATAGCTAACTGACG-3ʼ (F2). Reverse primer:
CTGCCACTGTCCTTCATTCC (R1) (Figure 2.1d, e). Sema3d expression in the adult
(two months old) tissue was analyzed using forward primer: 5ʼTGCTAGCAGGAAGGGTGAAC-3ʼ and reverse primer: 5ʼTAGGTTAGCTTGAGTCTTGG-3ʼ (Figure 2.1f). Sema3d control and mutant embryos on
a mixed sv129 and c57Bl/6 genetic background were analyzed at various developmental
stages for APVC [8 controls and 8 mutants at E16.5-E17.5 (3/8 mutants were affected),
16 controls and 11 mutants at E11.5-E12.5 (4/11 mutants were affected), 11 controls
and 10 mutants at E10.5 (4/10 mutants were affected), 10 controls and 9 mutants at
E9.5 (0/9 mutants were affected)].

Micro computed tomography:
MicroCT of iodine stained mouse tissue was performed as described (Degenhardt,
Wright et al.). Briefly, tissue was fixed in 4% paraformaldehyde. After fixation, tissue was
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washed in PBS and stained in 25% Lugolʼs solution prior to scanning. Reconstructed
data sets were viewed in Osirix (www.osirix-viewer.com) for figures and movies.

Optical projection tomography:
OPT was performed on both unstained and whole-mount immunostained embryos in a
Bioptonics OPT Scanner 3001M according to manufacturers instructions. Briefly,
wholemount immunostained embryos were embedded in agarose and dehydrated in
methanol, prior to clearing in benzyl alcohol – benzobenzoate (BABB) for scanning.
Reconstructed data sets were viewed in Osirix (www.osirix-viewer.com) for figures and
movies.

Immunohistochemistry:
Embryos were dissected in PBS and fixed immediately in 4% paraformaldehyde for 1620 h at 4 °C. Samples were washed with PBS, dehydrated in methanol series, and
stored in 100% methanol at –20 °C. Immunofluorescent detection of GFP (Abcam- cat.
no. AB6673, 1:100), PECAM1 (PharMingen- cat. no. 553370, 1:500), Ephb4 (R&D
Systems- cat. No. AF446, 1:100), phospho-histone H3 (Cell Signaling- cat. no. 9706,
1:200), and Nrp-1 (Abcam- cat. no. AB81321, 1:100) was performed on paraffin sections
of paraformaldehyde-fixed embryos. TUNEL staining was performed using standard
protocols. Whole-mount immunofluorescence studies of Sema3dGFPcre/+ and
Sema3dGFPcre/GFPcre embryos for Pecam1 and GFP were carried out as described (Singh,
Lu et al. 2011; Yokomizo, Yamada-Inagawa et al. 2012). Quantification of Pecam1
staining overlapping GFP positive cells was done with Image J (imagej.nih.gov/ij) on
stacks of confocal images. The ʻautoʼ setting was used for thresholding the green
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channel (GFP) to make a mask extending approximately 10 µM around each labeled
nucleus. The mask was then placed on the red (Pecam1) channel and measurements of
integrated density were taken.

Alkaline phosphatase binding assay:
The Sema3d coding sequence was cloned into the pAPtag5 plasmid (Merte, Wang et
al.) and transfected into HEK293T cells to produce conditioned media. Wild type and
variant forms of Sema3d-AP were expressed and secreted at similar levels. Binding to
transfected (with either empty vector, Nrp-1 or Nrp-2) Cos-7 cells was performed as
described (Gitler, Lu et al. 2004). Transfected cells were passaged into multiple wells
prior to exposure to Sema3d-AP ligands in order to ensure equal expression of putative
receptors in comparison groups. Equal molar ratios (as calculated from AP enzymatic
activity) of Sema3d-AP variants were incubated with transfected cells. Sema3d-AP
protein binding to tissue sections was performed as previously described (Gu, Yoshida
et al. 2005). Control (catalog no. AM4611) and Nrp-1 siRNA (catalog no. AM16704)
were purchased from Ambion. HUVECs were transfected with either control or Nrp-1
siRNA (200 nM) using RNAiMAX (Invitrogen, catalog no. 13778030) for 48 h before
Sema3d-AP binding. Nrp-1 knockdown was confirmed by RT-qPCR using Nrp-1 forward
(5ʼ-TATTCCCAGAACTCTGCCC-3ʼ) and Nrp-1 reverse (5ʼTGTCATCCACAGCAATCCCA-3ʼ) primers. Nrp-2 was used as control. Nrp-2 F primer:
5ʼ-CCTGTGGTTGGATGTATGAC-3ʼ. Nrp-2 R primer: 5ʼ-GCAGTTCTCCAGTGGGACAT3ʼ. All expression values were normalized to β–actin.

Endothelial cell repulsion assays:
	
  
	
  

	
  

45	
   	
  

	
  

Human umbilical vein endothelial cells (HUVEC lot #1023) and culture medium
(Vasculife EnGS Complete Kit, Cat. no. LL-0002) were purchased from Lifeline Cell
Technology and cultured according to the instructions of the manufacturer. HEK293T
cells in 10 cm cell culture plates were transiently transfected to generate virus with
either, pLOVE-Sema3d (WT), pLOVE-Sema3d (p.S65P), pLOVE-Sema3d (p.F602L), or
GFP in addition to pMD.G and psPAX2 using FuGene transfection reagent. Lentiviral
particles were collected after 24 and 48 h and concentrated using Millipore centrifugal
filter units. The presence of virus was confirmed with Clontech instant lentiviral titer tests.
HEK293 cells in 6 cm cell culture plates were subsequently infected with the harvested
virus for a period of 48 h. After 48 h, the infected HEK293 cells were resuspended in
media, washed, incubated with DiI solution, and plated on top of ~75% confluent HUVEC
cells. The mixture of cells was incubated for 24 h and observed with a Nikon Eclipse
TE200 inverted microscope under a 20× objective. For Nrp-1 blocking experiment,
soluble Nrp-1 (R&D systems, Cat. No. 566-N1, 5 nM) or a Nrp-1-specific antibody (R&D
systems, Cat. No. AF566, 1 μg ml–1) was added to the medium. Digital images were
captured and analyzed using ImageJ software. Cell-free areas surrounding infected cells
were measured (n = 10–26 cells per group).

Human genetics:
40 probands with a primary or secondary diagnosis of Total or Partial Anomalous
Venous Connection (21 probands with PAPVC and 19 probands with TAPVC) were
ascertained through the Department of Cardiothoracic Surgery at the Childrenʼs Hospital
of Philadelphia (CHOP) and voluntarily enrolled as part of an IRB approved protocol of
informed consent. PCR and sequencing primers were designed (using the ExonPrimer,
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a Primer3 based algorithm available on the UCSC Genome Browser
(http://genome.ucsc.edu/)) for the coding and flanking intronic regions of SEMA3D on
Chromosome 7. SEMA3D sequence annotation correlates to NM_152754. The primers
were synthesized by Integrated DNA Technologies (http://www.idtdna.com) and
reconstituted at 200 uM. Primer sequences, annealing temperatures and reaction
conditions are available upon request. PCR products were processed in the Nucleic
Acids and Protein Core Facility at CHOP according to their standard Sanger sequencing
protocol. Sequence analysis was carried out using both Sequencher v4.9 (Gene Codes
Corporation, Ann Arbor, MI) and MacVector (MacVector, Inc.) software. All sequencing
variants found were queried in the 1000 genomes database
(http://www.1000genomes.org/) and run through SIFT (http://sift.jcvi.org/) and PolyPhen
v2 (http://genetics.bwh.harvard.edu/pph2/) to predict potential pathogenicity. Any
variants not reported in the 1000 genomes database were first confirmed in the proband
and then tested in a cohort of 80 ethnically matched control samples. Due to the limited
quantity of DNA available for each proband (<500 ng), a whole genome amplification
(wga) reaction was required prior to PCR/sequencing. Briefly, 10 ng of each probandʼs
DNA was used as template in the commercially available GenomiPhi V2 DNA
Amplification kit (Illustra, Inc.) and each reaction was carried out according to the
manufacturerʼs protocol. Agarose gel electrophoresis was used to assess the quality of
the wga-DNA product. The final amplification product stocks for each proband were
diluted 1:20 and stored at –20 °C for use in downstream PCR/sequencing reactions.
Wga-DNA product was used as template for all initial screening reactions of SEMA3D
coding sequence. Upon identification of a novel coding variant in a probandʼs wga-DNA
sequence, the PCR/sequencing reaction was repeated using 20 ng of the original stock
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DNA to confirm the variant existed in the original proband DNA sample and was not
introduced by the wga reaction.

Statistical Analysis:
A two-tailed Studentʼs t-test or one-way ANOVA were used to analyze collected data that
fulfilled the criteria. Significant differences in the ANOVA were further analyzed post-hoc
by Tukeyʼs test for multiple comparisons (*P < 0.05; **P < 0.01; ***P < 0.001; NS, not
significant). All data expressed as the mean

	
  
	
  

	
  

S.E.M.
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Table 2.1
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Figure 2.1 Targeting strategy and verification of germline transmission for
Sema3d knockout allele
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Figure 2.1 Targeting strategy and verification of germline transmission for
Sema3d knockout allele
(a) Homologous recombination arms (~10 kb each) flank the start of translation site in
exon 2. Most of the coding region from exon 2 and the splice donor site are ablated and
replaced by a neomycin resistance gene (neo) in the targeting construct. Frt sites (black
triangles) flank the neo cassette. For negative selection, thymidine kinase (PGK-TK) is
included. The starting ATG is left intact, but is followed by stop codons in all three
reading frames (Stop × 3). EcoRV sites are located in the Sema3d locus outside the
regions of the homologous recombination arms and an additional site is within the neo
cassette. Orange arrows show the relative location of primers for PCR detection of
recombined embryonic stem (ES) cells (Sema3d-F and Sema3d-R), the wild type allele
(primers F1 and R1) and mutant allele (primers F2 and R1). (b) Representative PCR
screening of targeted ES cell clones. A large (10.9 kb) band indicates a properly targeted
clone. (c) Southern blot of ES cell DNA after EcoRV digestion shows wild type (~22 kb)
band and an additional smaller (~12 kb) band in a correctly targeted clone. (d) Southern
blot confirmation of germline transmission in mice (prior to excision of the neo cassette
with Flp recombinase). (e) Representative PCR genotyping results for wild type,
heterozygote and mutant mice after Flp recombination. The expected PCR product size
for the wild type allele is 927 bp and the expected size for the mutant allele is 985 bp.
Proper excision of the neo cassette was confirmed by sequencing the PCR product. (f)
Quantitative RT-PCR using primers for the deleted portion of the second exon confirms
absence of the normal transcript in adult tissues.
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Figure 2.2 Sema3d–/– mice have TAPVC
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Figure 2.2 Sema3d–/– mice have TAPVC
(a,b) Anterior views of wild type (a) and Sema3d–/– (b) hearts show severe cardiomegaly
in the mutants due to right atrial (RA) and right ventricular (RV) dilation. (a right, b right)
Pulmonary veins (PV) enter the left atrium (LA) in the wild type (a right) and the
coronary sinus (CS) in the mutant (b right). (c,d) Photomicrographs of H&E sections
showing normal connection to LA in wild type animals (c) and anomalous pulmonary
venous connections to the CS in Sema3d–/– mice (d). (e–h) Volume-rendered microCT
images (dorsal view) illustrate the pulmonary veins entering the posterior LA in control
(e) and entering the CS in a newborn mutant (g). (f,h) Diagram of microCT images
shown in (e,g) respectively. (i,j) M-mode echocardiograms through the ventricles of a
control (i) and a Sema3d–/– (j) heart shows relative dilation of the RV in an adult
Sema3d–/– mouse, and paradoxical septal wall motion indicative of right-sided volume
overload. LA – left atrium, LV – left ventricle, LU – lung, scale bar = 1 mm.
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Figure 2.3 Anomalous connections of the pulmonary veins to the right atrium in
Sema3d mutants
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Figure 2.3 Anomalous connections of the pulmonary veins to the right atrium in
Sema3d mutants
(a) Multiplanar reformatted OPT image shows the pulmonary vein (PV) as it enters the
right atrium (RA) in an E14.5 Sema3d mutant embryo. (b) H&E stained section of an
adult Sema3d–/– heart shows a pulmonary vein entering the RA. CS – coronary sinus,
RV – right ventricle, LV – left ventricle. Scale bar = 1 mm.
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Figure 2.4 Pulmonary vein patterning defects are detected in Sema3d–/– embryos
as early as E10.5.

	
  
	
  

	
  

56	
   	
  

	
  

Figure 2.4 Pulmonary vein patterning defects are detected in Sema3d–/– embryos
as early as E10.5.
(a,b) Volume rendered optical projection tomography (OPT) images of late stage (E17.5)
wild type (a) and Sema3d–/– (b) heart-lung blocks show normal pulmonary vein (PV)
connection to the LA in wild type, and connection to both the LA and CS in a Sema3d–/–
specimen. (c,d) Serial multiplanar reformatted OPT images of E12.5 wild type (c) and
Sema3d–/– (d) embryos show the course of the pulmonary vein from lung (LU) to the LA
in the wild type and to the CS in the mutant. See Supplementary movie 3 for additional
images. (e,f) Pecam1 immunofluorescence of E10.5 embryos shows the pulmonary
vascular plexus coalescing into the pulmonary vein (PV), which runs between the
mesocardial folds. In the wild type embryo (e) the PV remains near the midline, whereas
the Sema3d–/– PV deviates laterally, and there are ectopic vessels (arrowheads) (f).
(g,h) Pecam1 immunofluorescence at E9.5 shows no discernible abnormalities. Notably,
the midpharyngeal endothelial strand (MES) forms normally. Panels (g,h) are also
shown with adjacent sections in Figure 2.5. LA – left atrium, RA – right atrium, CS –
coronary sinus, RL – right lung bud, LL – left lung bud, scale bar = 100 μm.
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Figure 2.5 Vascular patterning appears normal in E9.5 Sema3d–/– embryos
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Figure 2.5 Vascular patterning appears normal in E9.5 Sema3d–/– embryos.
The top two rows show serial sections of Sema3d+/– and Sema3d–/– embryos from the
level of the common atrium (left most panel) dorsally to the anterior cardinal veins (right
most panels). Vascular patterning was visualized by Pecam1 immunohistochemistry.
The lower two rows show multiplanar reformatted OPT images of Pecam1 wholemount
immunostained embryos at roughly equivalent planes. In addition, nine wholemount
Pecam1 immunostained E9.5 embryos were examined by OPT (data not shown) with no
defects detected. Importantly, the midpharyngeal endothelial strand (MES) was present
in all embryos analyzed. Given, the prevalence of anomalous pulmonary veins in ~30%
of Sema3d–/– mice, the number of embryos analyzed gives >95% chance of observing a
defect at this stage if present. This argues against the long held view that failure of the
development of the normal pulmonary vein is the inciting event leading to TAPVC. A	
  

common atrium, V-ventricles, DA – dorsal aortae. Scale bar = 100 μm.

	
  
	
  

	
  

59	
   	
  

	
  

Figure 2.6 Sema3d-expressing cells form a boundary to restrict pulmonary
endothelium
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Figure 2.6 Sema3d-expressing cells form a boundary to restrict pulmonary
endothelium.
(a) Wholemount immunofluorescence for GFP in an E9.5 Sema3dGFPcre/+ embryo viewed
by OPT. The 3D volume rendered image is digitally cut in cross-section. Sema3d
expression marked by GFP (green) is in the mesocardial reflection and proepicardial
organ (PEO). (b) Pecam1 immunofluorescence of E9.5 Sema3dGFPcre/+ embryo highlights
the midpharyngeal endothelial strand (MES). (c) GFP Immunofluorescence of E10.5
Sema3dGFPcre/+ embryo at the level of the pulmonary vein (PV). (d) Adjacent section to (c)
with Nrp-1 immunofluorescence . (e) Co-immunofluorescence for Nrp-1 (red) and Ephb4
(green) at E11.5 shows that Nrp-1 expressing pulmonary vein (PV) endothelial cells also
express Ephb4. (f) Nrp-1 and Ephb4 are co-expressed by endothelial cells of the
cardinal veins (CV) but not the dorsal aorta (DA). (g) Sema3d-AP binding to E10.5
transverse sections (g left). Adjacent sections were stained with Pecam1 (g center).
Box shows area of forming pulmonary veins (PV). (h,i) 3D reconstruction of confocal
imaged E10.5 Sema3dGFPcre/+ (h) and Sema3dGFPcre/GFPcre (i) embryos stained for Pecam1
(red) and GFP (green). The 3D volume is digitally cut in cross section just above the PV
and viewed from a cranial perspective. (h right) A close up of the boxed region in (h
left). In mutants (i), Pecam1 positive endothelial cells (arrows) intermingle with GFPexpressing cells. (j) Quantification of the amount of Pecam1 staining within 10 µm of
GFP positive mesocardial cells in mutant and heterozygous embryos. *P < 0.05
(Studentʼs T-test). NT- neural tube, DA – dorsal aorta, RL – right lung bud, LL – left lung
bud, scale bar = 100 μm for a–g, 25 μm for h,i.
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Figure 2.7 Sema3d-expressing cells form a boundary to restrict pulmonary
endothelium.
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Figure 2.7 Nrp-1 is expressed by pulmonary vein endothelial cells during
development.
(a–l) Double immunofluorescence for Nrp-1 (green) and Pecam1 (red) at E9.5 (a–d),
E10.5 (e–h) and E11.5 (i–l). (d,h,l) show higher magnifications of the boxed regions in
(c,g,k), respectively. DA – dorsal aorta, MES – midpharyngeal endothelial strand, NTneural tube, RA-right atrium, RV-right ventricle, LV-left ventricle, V- ventricle, PVpulmonary vein, RL – right lung bud, LL – left lung bud. Scale bar = 100 μm.
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Figure 2.8 Pulmonary vein endothelial cell proliferation and survival is not
affected in Sema3d mutants
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Figure 2.8 Pulmonary vein endothelial cell proliferation and survival is not
affected in Sema3d mutants.
(a,b) Immunofluorescence for phospho-histone H3 (pHH3) and Nrp-1 using E11.5 wild
type and Sema3d–/– embryo sections at the level of the forming pulmonary veins (PV).
(c) Quantification of pHH3 and Nrp-1 double positive cells was performed on eight
sections from three individual embryos. (d,e) TUNEL assay for apoptotic cells was
performed on adjacent sections. No significant differences in cell proliferation or
apoptosis were observed. NS, not significant. Scale bar = 100 μm.
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Figure 2.9 Sema3d expression creates an avascular zone
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Figure 2.9 Sema3d expression creates an avascular zone.
Coimmunofluorescence for Pecam1 (red) and GFP (green) in a Sema3dGFPcre/+ E10.5
embryo shows an avascular region just caudal to the pulmonary vein (a–c). The
pulmonary vascular plexus has been shown to separate from greater vascular plexus
within the splanchnic mesoderm. The beginning of this separation occurs just caudal to
the connection with the atria. Sagittal images of wholemount double stained embryos
shows the area where this separation begins. An avascular zone overlaps with the
region of expression from the Sema3d locus (green) just caudal to the vascular
connection with the atria. (d–g) Off axis sagittal sections of a different control
Sema3dGFPcre/+ embryo shows the region of GFP expression highlighted in the dashed
oval. (g) Higher magnification of the area boxed in panel (f). (h–k) Mutant embryos,
Sema3dGFPcre/GFPcre, at the same angle as (d–g), show incomplete separation of the
pulmonary vein from the greater splanchnic plexus. This occurs where endothelial cells
invaded the region that the Sema3d locus is active (as marked by GFP). (k) Higher
magnification of the region boxed in (j). Scale bar = 100 μm.
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Figure 2.10 Chromatogram of Sema3d variant.
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Figure 2.10 Chromatogram of Sema3d variant.
Forward and reverse sequence chromatograms of an APVC proband showing Sema3d
(p.F602L) variant resulting in a phenylalanine to leucine substitution of amino acid 602,
and a forward sequence chromatogram of a control individual. The individual bearing this
variant was Caucasian and had PAPVC and a ventricular septal defect. NCBI reference
sequence NM_152754 version NM_152754.2 GI: 41406085.
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Figure 2.11 Sema3d binds to Nrp-1 and is capable of repelling endothelial cells.

	
  
	
  

	
  

70	
   	
  

	
  

Figure 2.11 Sema3d binds to Nrp-1 and is capable of repelling endothelial cells.
(a) Wild type Sema3d and variants found in individuals with APVCs were tested in the
context of alkaline phosphatase (AP) fusion proteins for binding to Nrp-1 and Nrp-2
overexpressed in Cos-7 cells. Sema3f-AP was included as a positive control for binding
to both neuropilins. (b) Representative photomicrographs of diI (red) labeled HEK293
cells transduced with Sema3d or control (GFP) lentivirus, and co-cultured with HUVECs.
Repulsion results in a cell-free area (dotted yellow lines) surrounding HEK293 cells. (c)
Quantification of cell free area surrounding HEK293 cells. Sema3d and Sema3d(p.S65P)
display similar abilities to repel HUVECs. Sema3d(p.F602L) shows markedly reduced
repulsion. GFP control transduced cells do not repel HUVECs. **P < 0.01 (One-way
ANOVA between groups, P < 0.001; Post-hoc multiple comparisons, Tukeyʼs test). (d–e)
Effect of soluble Nrp-1 (Nrp-1-Fc) (5 nM) and a Nrp-1-specific blocking antibody (Nrp-1
ab) (1 μg ml–1) on Sema3d mediated endothelial cell repulsion. Blocking Nrp-1 signaling
significantly reduced Sema3d mediated HUVEC repulsion. (f) Model depicting the role of
Sema3d in pulmonary vein patterning. *P < 0.05, **P < 0.01 (One-way ANOVA between
groups P < 0.001, P < 0.01; Post-hoc multiple comparisons, Tukeyʼs test). Scale bar =
100 μm
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Figure 2.12 Sema3d(p.F602L) variant binds Nrp-1 expressing cells more weakly
than wild type Sema3d.
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Figure 2.12 Sema3d(p.F602L) variant binds Nrp-1 expressing cells more weakly
than wild type Sema3d.
(a) Photomicrographs of Nrp-1 transfected Cos-7 cells after binding to Sema3d-AP,
Sema3d (p.S65P)-AP, Sema3d(p.F602L)-AP, or control alkaline phosphatase (AP). (b)
Intensity of staining was quantified based on photomicroscopy after alkaline
phosphatase color reaction on the basis of average integrated density using ImageJ. ***
P < 0.001. Scale bar = 100 μm.
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Figure 2.13 Sema3d(p.F602L) variant binds HUVECs more weakly than wild type
Sema3d.
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Figure 2.13 Sema3d(p.F602L) variant binds HUVECs more weakly than wild type
Sema3d.
(a) Photomicrographs of HUVECs after binding to Sema3d-AP, Sema3d (p.S65P)-AP,
Sema3d(p.F602L)-AP, or control alkaline phosphatase (AP). (b) Intensity of staining was
quantified based on photomicroscopy after alkaline phosphatase color reaction on the
basis of average integrated density using ImageJ. *** P < 0.001. NS, not significant.
Scale bar = 100 μm.
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Figure 2.14 Knockdown of Nrp-1 in HUVECs significantly reduces Sema3d-AP
binding.
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Figure 2.14 Knockdown of Nrp-1 in HUVECs significantly reduces Sema3d-AP
binding. (a) Photomicrographs of HUVECs after binding to Sema3d-AP fusion protein.
HUVECs were transfected with either control siRNA or Nrp-1 siRNA 48hrs before
binding. (b) Intensity of staining was quantified based on photomicroscopy after alkaline
phosphatase color reaction on the basis of average integrated density using ImageJ. ***
P < 0.001 (c) Nrp-1 knockdown was confirmed by qRT-PCR. Scale bar = 100 μm.
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Chapter 3 : Mechanisms of Semaphorin 3d signaling to endothelial cells
In this chapter I continue my exploration of Sema3d signaling and mechanisms presented in
Chapter 2. This work was done with the help of a medical student Connie Choi who visited our lab
for a year. Much of this chapter was published as a cover article in the Journal of Biological
Chemistry (Aghajanian et al. 2014).

Summary
	
  
Class 3 semaphorins were initially described as axonal growth cone guidance molecules
that signal through plexin and neuropilin coreceptors, and since have been established
to be regulators of vascular development. Semaphorin 3e (Sema3e) was previously
shown to repel endothelial cells and is the only class 3 semaphorin known to be capable
of signaling via a plexin receptor without a neuropilin coreceptor. Sema3e signals
through plexin D1 (Plxnd1) to regulate vascular patterning by modulating the
cytoskeleton and focal adhesion structures. Recently, we have shown that semaphorin
3d (Sema3d) mediates endothelial cell repulsion and pulmonary vein patterning during
embryogenesis. Here we show that Sema3d and Sema3e similarly affect human
umbilical vein endothelial cells (HUVECs) but through distinct molecular signaling
pathways. Time-lapse imaging studies show that both Sema3d and Sema3e can inhibit
cell motility and migration, and tube formation assays indicate that both can impede
tubulogenesis. Endothelial cells incubated with either Sema3d or Sema3e demonstrate a
loss of actin stress fibers and focal adhesions. However, the addition of neuropilin 1
(Nrp1) blocking antibody or siRNA knockdown of Nrp1 inhibits Sema3d-mediated but not
Sema3e-mediated cytoskeletal reorganization, and siRNA knockdown of Nrp1 abrogates
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Sema3d but not Sema3e-mediated inhibition of tubulogenesis. On the other hand,
endothelial cells deficient in Plxnd1 are resistant to endothelial repulsion mediated by
Sema3e, but not Sema3d. Unlike Sema3e, Sema3d incubation results in
phosphorylation of Akt in HUVECs, and inhibition of the Phosphoinositide 3-kinase
(PI3K)/Akt pathway blocks the endothelial guidance and cytoskeletal reorganization
functions of Sema3d but not Sema3e.

Introduction

Patterning of the vascular system requires coordinated temporal and spatial direction to
the developing endothelium together with the ability of the endothelium to receive
guidance signals. This is accomplished by a combination of secreted attractive and
repulsive cues as well as cell-to-cell communications (Larrivee, Freitas et al. 2009).
Disruption of these signaling pathways can result in improper endothelial cell guidance,
developmental pathologies, and disease (Auerbach and Auerbach 1997).

Semaphorins are a family of secreted and transmembrane signaling molecules that have
been implicated in numerous and diverse biological processes (Kruger, Aurandt et al.
2005). Originally discovered as axon guidance molecules (Luo, Raible et al. 1993),
semaphorins have since been implicated in vascular patterning, tumor progression, and
immune cell regulation (Bougeret, Mansur et al. 1992; Gitler, Lu et al. 2004; Neufeld and
Kessler 2008). The class of secreted vertebrate semaphorins, class 3 (Sema3 proteins),
has been shown to be particularly important in proper cardiovascular development (Gu
and Giraudo 2013). Loss of Sema3c in mice results in aortic arch malformations as well
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as defects of outflow tract septation (Feiner, Webber et al. 2001). Sema3e is required for
intersomitic vessel and aortic patterning (Gu, Yoshida et al. 2005; Meadows, Fletcher et
al. 2012), and most recently we have demonstrated that Sema3d is necessary for proper
pulmonary vein development and connection (Degenhardt, Singh et al. 2013).

Several class 3 semaphorins can affect migration and motility of endothelial cells (Kigel,
Varshavsky et al. 2008), and this function is what is believed to be responsible for
Sema3 mediated cardiovascular development. Canonical Sema3 protein signaling
involves neruopilin/plexin heterodimeric receptors (Sharma, Verhaagen et al. 2012). With
the exception of Sema3e, which can signal through Plxnd1 alone (Gu, Yoshida et al.
2005), all other Sema3 proteins are thought to require either neuropilin 1 (Nrp1) or
neuropilin 2 (Nrp2) co-receptors. Although Sema3 proteins are capable of exerting both
an attractive and repellent effect on neurons (Sharma, Verhaagen et al. 2012), in general
their effect on endothelial cells appears to be of a repellent nature. The mechanism of
endothelial repulsion in the case of Sema3e is a result of loss of focal adhesions and
dismantling of the actin cytoskeleton (Sakurai, Gavard et al. 2010). The mechanisms of
other Sema3 protein mediated endothelial repulsion remain poorly elucidated.

In this study we show that Sema3d, like Sema3e, is capable of inhibiting endothelial cell
motility, migration, and tube formation. Both of these Sema3 proteins accomplish these
tasks by affecting cytoskeletal dynamics and cell adhesion. Interestingly, the
mechanisms by which these two Sema3 ligands exert such similar effects on endothelial
cells diverge at the level of receptor signaling. Unlike Sema3e, Sema3d does not require
Plxnd1 for endothelial repulsion. And whereas Sema3d mediated inhibition of endothelial
	
  
	
  
80	
   	
  
	
  
	
  

tube formation and cytoskeletal rearrangements require Nrp1, Sema3e mediates these
effects independently of Nrp1. We also observe distinct signaling pathways downstream
of the receptors for these two Sema3 proteins.
Results

Sema3d and Sema3e inhibit endothelial cell motility and tubulogenesis.
To examine the effects of Sema3d and Sema3e on endothelial cell motility and
migration, human umbilical vein endothelial cells (HUVECs) were incubated with equal
concentrations (10nM) of Sema3d or Sema3e and live-imaged for 3 hours. A compilation
of the tracks corresponding to individual endothelial cell migration paths showed that
both Sema3d and Sema3e significantly decreased the total distance and the maximum
displacement traveled by the cells compared to controls (Figure 3.1a, b). Moreover,
HUVECs appeared to lose directional motility in the presence of both Sema3d and
Sema3e, as they failed to migrate away from the point of origin as measured by
maximum displacement normalized to total distance for each track. These data suggest
that Sema3d and Sema3e mediate endothelial cell repulsion through inhibition of general
and directed cell motility.

We assessed how Sema3d and Sema3e affect the ability of HUVECs to form capillarylike tubes on a basement membrane matrix. This assay allows us to investigate the
effects of these Sema3 proteins on the endothelial cell migration and rearrangements
necessary in angiogenesis. Both Sema3d and Sema3e significantly inhibited tube
formation by HUVECs after 8 hours when compared with controls (Figure 3.1c, d).
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These results demonstrate that both Sema3d and Sema3e similarly inhibit functional
abilities of endothelial cells that are necessary for proper vascular development.

Sema3d mediated endothelial repulsion does not require Plxnd1.
In order to compare the chemotactic properties of Sema3d and Sema3e on endothelial
cells, we employed a transwell migration assay. It was previously shown that endothelial
cells are inhibited from migrating through a membrane towards a Sema3e gradient
(Casazza, Finisguerra et al. 2010). To assess the necessity of Plxnd1 in this assay,
endothelial cells were isolated from embryonic day 16.5 Plxnd1+/– and Plxnd1–/– mice.
Both Sema3d and Sema3e were capable of inhibiting migration of Plxnd1+/– endothelial
cells through a transwell membrane as compared with controls (Figure 3.2a). As
expected, Sema3e was unable to inhibit migration of Plxnd1–/– endothelial cells (Figure
3.2b, c). In contrast, Sema3d was able to inhibit endothelial migration even in the
absence of Plxnd1 expression (Figure 3.2b, c). These results provide evidence of
divergent signaling pathways for Sema3d vs. Sema3e despite similar functional
activities.

Sema3d and Sema3e cause loss of actin stress fibers and focal adhesions in endothelial
cells.
We next sought to investigate the cellular mechanisms by which these Sema3 proteins
affect migration and motility. We compared the effects of Sema3d and Sema3e on actin
stress fiber and focal adhesions in HUVECs. HUVECs were incubated with alkaline
phosphatase (AP) tagged Sema3d, AP-Sema3e or AP alone in equal amounts as
quantified by alkaline phosphatase activity. Both Sema3 proteins caused endothelial
	
  
	
  
82	
   	
  
	
  
	
  

cells to lose their cytoskeletal stress fibers (Figure 3.3a). The percent of cells with a loss
of stress fibers was significantly more in both the Sema3d and Sema3d groups in as little
as 15 minutes as compared with control (Figure 3.3b). Loss of actin stress fiber
occurred at a similar rate in response to Sema3d vs. Sema3e, and more than 80% of the
exposed cells had lost stress fibers by 60 minutes (Figure 3.3a, b).

Concurrent with loss of actin stress fibers, focal adhesions (FAs), which adhere the
cytoskeleton to the extra-cellular matrix, also decreased after exposure to Sema3d or
Sema3e as visualized by the FA marker vinculin (Figure 3.3a). Quantification of the
number of FAs per cell revealed a statistically significant decrease at 15 minutes with
Sema3d (P < 0.01) or Sema3e (P < 0.01) and a continued decline thereafter when
compared with controls (Figure 3.3c). A cell adhesion assay revealed that Sema3d and
Sema3e were able to significantly inhibit HUVEC adhesion to a collagen matrix after 30
minutes of incubation (Figure 3.3d). These results suggest that both Sema3d and
Sema3e signal to modify the organization of the endothelial cell cytoskeleton and
adhesion in a grossly similar manner.

Sema3d mediated endothelial cell cytoskeletal reorganization and tubulogenesis is
dependent on Nrp1.
We examined the role of Nrp1 in Sema3d- and Sema3e-mediated cytoskeletal
rearrangement in HUVECs by incubating cells with a blocking anti-Nrp1 antibody and
either Sema3d or Sema3e. Visualization of actin and vinculin showed that blocking Nrp1
inhibited Sema3d mediated but not Sema3e mediated cytoskeletal changes (Figure
3.4a, b). Knockdown of Nrp1 in HUVECs using Nrp1 siRNA also showed that Sema3d,
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but not Sema3e, requires Nrp1 to dismantle the cytoskeleton (Figure 3.4c). The ability of
Sema3d to inhibit tubulogenesis was also dependent on Nrp1, while the activity of
Sema3e in this assay was unaffected by Nrp1 knockdown (Figure 3.4d, e). Therefore,
Sema3d and Sema3e engage endothelial cells via different receptor complexes to
mediate similar effects on migration, tubulogenesis and cytoskeletal reorganization.

Sema3d signals through the PI3K/Akt pathway.
During a screen of intermediate signaling molecules involved in cytoskeletal dynamics,
we found that Sema3d increased the phosphorylation of Akt in HUVECs (not shown).
We confirmed this result and also determined that this effect was not seen in response to
Sema3e (Figure 3.5a,b). Further examination revealed that Sema3d incubation
increased Akt phosphorylation in HUVECs in a dose dependent manner (Figure 3.5c).
To test whether the PI3K/Akt pathway was necessary for functional Sema3d signaling,
we employed a transwell endothelial cell migration assay. Similar to the repulsion seen
using Plexind1+/– endothelial cells (Figure 3.2a), both Sema3d and Sema3e were able to
inhibit HUVECs from migrating through a transwell insert compared to vehicle control
(Figure 3.5d). However, incubation with the PI3K inhibitor Wortmannin abrogated the
ability of Sema3d to inhibit endothelial migration, but did not have an effect on Sema3e
mediated inhibition (Figure 3.5d).

To investigate whether the PI3K dependent repulsive action of Sema3d on endothelial
cells was due to actin cytoskeletal regulation we visualized actin stress fibers in Sema3d
or Sema3e incubated HUVECs in the presence or absence of the potent PI3K inhibitor
Wortmannin (Figure 3.5e). As shown previously, Sema3d caused HUVECs to lose actin
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stress fibers, but this response was greatly attenuated in the presence of Wortmannin
(Figure 3.5f). In contrast, Wortmannin had no effect on Sema3e mediated actin
reorganization.

Discussion

Our results indicate that Sema3d and Sema3e are capable of exerting similar effects on
endothelial cells, but that these effects are mediated by distinct molecular signaling
pathways. We show that Sema3d signals through Nrp1 and PI3K independently of
Plxnd1, and Sema3e signals through Plxnd1 independently of Nrp1, while achieving
similar functional endpoints. It will be of interest to determine the details of the
intracellular signaling pathways activated in response to various class 3 semaphorins,
and at which points signaling via Sema3d and Sema3e converge. In this regard, the
details of how plexin and neuropilin receptors signal are only partially understood, and
the complexity of Sema3 ligand-receptor interactions continues to emerge in the
literature. While Sema3e can signal via Plxnd1 alone, the full description of the functional
Sema3d receptor(s) are unknown and remain elusive, although our work indicates that
Nrp1 is a necessary component of the Sema3d receptor in endothelial cells. We have
been unable to detect binding of Sema3d to any of the plexins we have examined
including Plexins A1, A2, A3, B2, and D1 (data not shown). In addition to plexin
receptors, we have not detected binding of Sema3d to other candidate co-receptors
including Pdgfra, Pdgfrß, Vegfr1, Vegfr2, or Vegfr3 (data not shown).
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We demonstrate that Sema3d, but not Sema3e, induces Akt phosphorylation in HUVECs
and requires PI3K signaling for endothelial repulsion. This is in contrast to the several
class 3 semaphorins that negatively regulate Akt signaling. Sema3a, Sema3b, and
Sema3f have all been shown to inhibit or decrease Akt phosphorylation in various cell
types (Atwal, Singh et al. 2003; Chadborn, Ahmed et al. 2006; Guan, Villegas et al.
2006; Potiron, Sharma et al. 2007; Castro-Rivera, Ran et al. 2008). Sema3e can inhibit
Vegf mediated Akt phosphorylation in endothelial cells (Moriya, Minamino et al. 2010),
but can also increase Akt phosphorylation in subicular neurons (Bellon, Luchino et al.
2010). Our results provide an example of semaphorin mediated endothelial guidance
requiring the PI3K/Akt signaling pathway.

Although our results suggest that Sema3d and Sema3e produce similar effects on
endothelial cells, it remains possible that unique functions exist for Sema3d or Sema3e
that were not detected by our assays. Sema3e signaling, for example, can induce
apoptosis in tumor endothelial cells (Casazza, Finisguerra et al. 2010). Sema3c
promotes proliferation and inhibits apoptosis of mouse glomerular endothelial cells as
well as affecting migration (Banu, Teichman et al. 2006). Sema3a inhibits cancer cell
proliferation and causes cellular contraction (Sabag, Bode et al. 2012). Though Sema3b
can induce similar morphologic contraction in these cells, it does not have the same
effect on cell proliferation. The effects of Sema3d and Sema3e may also depend upon
the specific type of endothelial cells that are utilized. Although our studies focused on
HUVECs, it is becoming increasingly clear that important heterogeneity exists between
endothelial populations (Yamamizu and Yamashita 2011). For example, arterial, venous
and lymphatic endothelial cells differentially express neuropilin, Vegf and Notch
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receptors. Perhaps guidance queues mediated by Sema3 proteins are differentially
interpreted by arterial, venous and lymphatic endothelium based in part upon receptor
availability. It is worth noting that the primary defect resulting from Sema3d inactivation
in the mouse is mis-patterning of the pulmonary veins (Degenhardt, Singh et al. 2013),
while inactivation of Sema3e produces abnormalities of intersomitic arteries (Gu,
Yoshida et al. 2005).

In neurons, the cellular response to a given Sema3 protein may be dependent upon the
receptor complexes that are expressed, and different receptors can produce opposing
responses to the same ligand. During mouse neural development, for example, neurons
that express both Plxnd1 and Nrp1 are attracted to Sema3e and migrate towards the
signal (Chauvet, Cohen et al. 2007). In contrast, neurons expressing only Plxnd1 are
repelled by Sema3e. Similarly in zebrafish, sema3d can act as a repellent signal to
axons expressing nrp1A, and as an attractant to axons expressing both nrp1A and
nrp2A (Wolman, Liu et al. 2004). Sema3e can also signal through a heterotrimeric
receptor complex composed of Plxnd1, Nrp1, and Vascular endothelial growth factor 2
(Vegfr2) to promote axonal growth (Bellon, Luchino et al. 2010). In contrast, Sema3e
inhibits growth of axons expressing Plxnd1 only. The effects of Sema3 proteins are also
modulated by variable expression of intracellular signaling components. In the central
nervous system, for example, the ability of Sema3f to induce stereotyped axonal pruning
of neurons originating in the dentate gyrus is dependent upon the presence of an intracellular RacGTPase activating protein called β2-chimaerin which binds to the
intracellular domain of Nrp2 and is activated by Sema3f binding (Riccomagno, Hurtado
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et al. 2012). The ability of Sema3f to induce axon repulsion, however, does not require
ß2-chimaerin.

Nrp1, which we have shown is necessary for Sema3d repulsion of HUVECs, has also
been demonstrated to serve as a subunit of a receptor for vascular endothelial growth
factor (Vegf). Sema3 competition with Vegf for neuropilin binding can inhibit the
angiogenic effects of Vegf on endothelium (Parker, Linkugel et al. 2013). Furthermore,
different members of the Sema3 family compete with Vegf with varying potency. We and
others have recently shown that semaphorin-Plxnd1 activity can modulate VEGF
signaling by inducing secretion of a soluble Vegf receptor (sFlt1)(Zygmunt, Gay et al.
2011) and, conversely, Vegf can also act upstream of Plxnd1 to regulate its expression
(Kim, Oh et al. 2011). The result of Vegf and semaphorin integration modulates Notch
signaling in tip and stalk cells of angiogenic sprouts and the combined actions of these
signals contribute to determination of tip and stalk cell identity and the angiogenic
response. It seems likely that Sema3d and Sema3e will variably modulate and intersect
with other important angiogenic and antiangiogenic pathways, including Vegf.

The range and diversity of cellular effects in response to Sema3 proteins in different cell
types speaks to the complexity of Sema3 protein-receptor signaling. We demonstrate
that Sema3d and Sema3e can similarly affect endothelial motility and migration through
distinct cellular mechanisms. Sema3e-Plxnd1 signaling in endothelial cells relies on the
GTPase activating protein (GAP) activity of Plxnd1 to inactivate R-Ras and activate Arf6
to modulate the cytoskeleton and cellular adhesion (Sakurai, Gavard et al. 2010). It will
be of interest to investigate these pathways in Sema3d signaling in endothelial cells and
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whether Sema3d requires a plexin co-receptor or an alternate signaling partner in
association with Nrp1.

Materials and Methods
Cell Culture:
HEK293T cells were cultured in Dubeccoʼs modified Eagleʼs media (DMEM) from Sigma
with 10% fetal bovine serum (FBS). Primary human umbilical vascular endothelial cells
(HUVECs) (lot #1023) were cultured in human endothelial cell culture media, VascuLife®
EnGS (#LL-0002) (basal EnGS media, 0.2% EnGS, 5 ng/ml rh EGF, 50 µg/ml ascorbic
acid, 10 mM L-glutamine, 1.0 µg/ml hydrocortisone hemisuccinate, 0.75 U/ml heparin
sulfate and 2%) from Lifeline Cell Technology.

Reagents and Antibodies:
Human recombinant Sema3e (#3239-S3-025), human recombinant Sema3d, and Antineuropilin 1 antibody (#AF566) were obtained from R&D Systems. Anti-phospho- Akt
(#4060), Anti-Akt (#9272), anti-β-actin (#4967), and Wortmannin (#9951) were
purchased from Cell Signaling. Lipofectamine 2000 (Invitrogen) was used as the
transfection reagent for HEK293T cells, Phallodin rhodamine (#PHDR1) was purchased
from Cytoskeleton. Anti-vinculin antibody (#V9131) and CytochalasinD (#C2618) were
obtained from Sigma Aldrich. Prolong Gold Antifade Reagent with DAPI (#P36935) and
Alexa Fluor 488 Goat Anti-mouse (#A11001) was obtained from Invitrogen. AP Assay
Reagent A (#Q501) was obtained from GenHunter®. Coverslips and tissue culture plates
were coated with type I rat tail collagen (#CB40236) from BD Biosciences.
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Tubulogenesis assays were performed using Matrigel® Growth Factor Reduced
(#354230, lot #2222781, endotoxin=3.4) from BD Biosciences.

Production and Quantification of Conditioned Media:
HEK293T cells were transfected with Sema3d-pAPtag5 plasmid, Sema3e-AP-pA6 or
pAPtag4 plasmid in antibiotic-free DMEM with 10% FBS. After 24 hrs, the media was
changed to DMEM with 1% FBS and penicillin-streptomycin. After 48 hrs, the
conditioned media was collected. YFP-PCDMA3.2 plasmid transfected into HEK-293T
cells was used as a transfection control. A 50μl sample of the conditioned media was
incubated at 65°C for 15 mins to inactivate endogenous AP activity. 50μl of AP Assay
reagent A (2M diethanolamine, 1 mM MgCl, 1 mg/ml BSA and 24 mM pnitrophenylphosphate, pH 6.8) was added to the conditioned media and incubated at
37°C for 10 min. 100μl 0.5N NaOH was added to stop the reaction. Absorbance was
measured at 405nm.

Microscopy and Image Analysis:
For time-lapse experiments, HUVECs were cultured in a Nikon BioStation IM live cell
recorder for 3 hours in the presence of 10nM recombinant Sema3d, 10nM recombinant
Sema3e, or vehicle (PBS). Images were recorded with BioStation IM software. For
immunofluorescence experiments, HUVECs were cultured on collagen-coated
coverslips. They were treated with 10nM recombinant Sema3d, 10nM recombinant
Sema3e, or vehicle (PBS). Alternatively, they were incubated with conditioned media
containing equal quantities of Sema3d-AP, Sema3e-AP, or AP at 37°C where indicated
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as measure by alkaline phosphatase activity. The HUVECs were subsequently fixed
with 3.7% formaldehyde for 10 min and permeabilized with 0.5% Triton for 5 min. Cells
were stained with phalloidin rhodamine for 30 min, blocked with 2% w/v non-fat milk in
dPBS for 60 min, incubated with anti-vinculin antibody for 60 min, and then Alexa Fluor
488 anti-mouse IgG for 60 min. Coverslips were mounted with media containing DAPI
stain, and the cells were visualized on a Nikon Eclipse80i microscope using NIS
Elements software. Segmentation and quantification of focal adhesions were achieved
using ImageJ software (Schneider, Rasband et al. 2012). A threshold was applied to
vinculin stained images based on measurements of the mean gray value to exclude nonfluorescent background pixels. “Analyze Particles” function was then used to count focal
adhesions. Particles smaller than 1μm2 or with a circularity greater than 0.75 were
excluded based on the sizes and shapes of previously published vinculin positive focal
adhesions (Kim and Wirtz 2013).

Matrigel Tubulogenesis Assay:
Reduced growth factor Matrigel (289μl/well) was plated in the wells of a 24-well plate.
Plate was incubated at 37°C for 30 min. HUVECs (6x104 cells/well) were plated and
recombinant Sema3d (2μg/ml), Sema3e (2μg/ml), IgG (3.6μg/ml), Cytochalasin D
(50ng/ml) or DMSO (2μl) was added to the appropriate well. The cells were incubated for
8 hrs and visualized on an inverted Nikon Eclipse TE200 microscope using Capture
Advanced software.

RNA interference:
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HUVECs were transfected with Lipofectamine RNAiMAX using Nrp1 pre-designed
siRNA (Ambion, #4914) or Silencer Negative control siRNA #1 (Ambion, AM4611) in
antibiotic-free media. The media was changed to complete HUVEC media after 24 hrs,
and the cells were used at 48 hrs.

Endothelial Isolation:
Timed pregnant female from a Plxnd1 heterozygous mouse cross was sacrificed at
embryonic day 16.5. Embryos were assessed for the presence of persistent truncus
arteriosis (PTA) to identify nulls and subsequently genotyped for verification. Embryos
(absent the head, heart, lungs, and liver) were minced and incubated with collagenase A
(Sigma, C-0130). Single cell suspension was achieved by passing the cells through
small gauge syringes and a 40µm nylon cell strainer. Cells were incubated with a
PECAM antibody (BD Pharmigen, 557355) for 30 mins at 4°C, washed, incubated with
Protein G Dynabeads (Life Technologies, 10003D), and washed again. Dynabeads were
plated onto a fibronectin (Roche, 11051407001) in endothelial cell media.

Transwell Migration:
Transwell inserts (BD Biosciences, 353097) in triplicate were coated on the underside
with 10µg/ml fibronectin (Roche, 11051407001) and placed in individual wells of a 24
well plate containing either 10nM recombinant Sema3d, 10nM recombinant Sema3e, or
vehicle (PBS) in DMEM. Endothelial cells were trypsinized, re-suspended in DMEM
containing 0.2% BSA (Gemini, 700-101P), and 105 cells were seeded in each insert and
allowed to migrate for 5 hours. For inhibitor experiments, the cells were re-suspended in
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media containing either Wortmannin (1 μM) or a DMSO vehicle control when seeded in
the inserts. The migrated cells were fixed in 4% paraformaldehyde for 2 mins,
permeabilized in methanol for 20 mins, and stained with giemsa (Sigma, GS-500) for 25
mins. Cell that did not migrate were scraped from the inside of the insert with a cotton
swab. Three high power fields of each insert were imaged using an Olympus MVX10
microscope and quantified using ImageJ.

Cell Adhesion Assay:
Collagen I coated cell adhesion plates (Cell Biolabs, CBA-052) were allowed to warm to
room temperature for 10 minutes. HUVECs were re-suspended in DMEM containing
0.2% BSA and either 10nM Sema3d, 10nM Sema3e or a vehicle control. 3x105 cells
from each condition were transferred to individual wells and incubated for 30 minutes.
Non-adherent cells were washed away, the remaining cells stained and extracted, and
the optical density was measured at 560 nm.

Western Blotting:
Blots were probed with anti-phospho-Akt (1:2000), anti-Akt (1:1000), or anti-β-actin
(1:1000) as per manufacturerʼs instructions. Visualization was achieved using ECL Prime
(GE Life Sciences). Quantification of individual band intensity was performed using
ImageJ.

Statistical Analysis:
One-way analysis of variance (ANOVA) was used to assess statistical differences
between groups. Significant ANOVA results were further analyzed by Tukeyʼs multiple
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comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant. All data is
represented as the mean ± standard error of the mean (SEM).
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Figure 3.1 Sema3d and Sema3e inhibit endothelial cell motility and tubulogenesis.
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Figure 3.1 Sema3d and Sema3e inhibit endothelial cell motility and tubulogenesis.
(a) Tracks represent the migration paths of individual HUVECs incubated with Sema3d,
Sema3e, or vehicle control for 3 hours. (b) Quantification of total distance (µm) and
maximum displacement (µm) of HUVECs in each condition. ***P < 0.001 (one-way
ANOVA between groups P < 0.001; post-hoc multiple comparisons, Tukeyʼs test). (c)
Photomicrographs of HUVECs seeded in Matrigel and incubated with Sema3d, Sema3e,
Cytocholasin D, or vehicle control for 8 hours. Cytochalasin D is used as a positive
control for inhibition of tubulogenesis. (d) Quantification of the number of tubules formed
per high power field. **P < 0.01, ***P < 0.001 (one-way ANOVA between groups P <
0.001; post-hoc multiple comparisons, Tukeyʼs test, n = 9). Scale bars = 50 µm (a), 1
mm (c).
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Figure 3.2 Sema3d inhibits endothelial migration independent of Plxnd1
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Figure 3.2: Sema3d inhibits endothelial migration independent of Plxnd1.
(a) Graph representing the percentage of Plxnd1+/– endothelial cells that migrated
through a porous transwell insert in the presence of Sema3d or Sema3e compared with
vehicle control. ***P < 0.001 (one-way ANOVA between groups P < 0.001; post-hoc
multiple comparisons, Tukeyʼs test, n = 3). (b) Graph representing the percentage of
Plxnd1–/– endothelial cells that migrated through a porous transwell insert in the
presence of Sema3d or Sema3e compared with vehicle control. **P < 0.01, ns = not
significant (one-way ANOVA between groups P < 0.001; Post-hoc multiple comparisons,
Tukeyʼs test, n = 3). (c) Photomicrographs of stained endothelial cells that migrated
through a transwell membrane in the presence of vehicle (left), Sema3d (center), or
Sema3e (right). Scale bar = 100 µm.
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Figure 3.3 Sema3d and Sema3e induce loss of actin stress fibers and downregulate focal adhesion complexes.
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Figure 3.3 Sema3d and Sema3e induce loss of actin stress fibers and downregulate focal adhesion complexes.
(a) HUVECs were incubated with alkaline phosphatase-tagged Sema3d, Sema3e, or
alkaline phosphatase alone (AP) as a control for 0, 15, 30, 45 and 60 mins and stained
for F-actin (red) and vinculin (green). (b) Quantification of the percentage of HUVECs
displaying loss of actin stress fibers at each time point. (n=60 cells per condition) (c)
Quantification of the number of vinculin units per HUVEC at each time point. (n=10 cells
per condition) (d) Percentage of HUVEC adhesion to collagen I after a 30-minute
incubation with Sema3e, Sema3d, or a vehicle control as quantified by a colorimetric
assay. *P < 0.05, ***P < 0.001 (one-way ANOVA between groups; post-hoc multiple
comparisons, Tukeyʼs test, n = 5). Scale bars = 50 µm (smaller bar), 5 µm (larger bar).
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Figure 3.4 Sema3d-meidated but not Sema3e-mediated cytoskeletal
reorganization and inhibition of tubulogenesis is dependent on Nrp1
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Figure 3.4 Sema3d-meidated but not Sema3e-mediated cytoskeletal
reorganization and inhibition of tubulogenesis is dependent on Nrp1.
(a) HUVECs were exposed to Sema3d, Sema3e, or vehicle control with or without an
anti-NRP-1 blocking antibody for 60 min and subsequently stained for F-actin (red) and
vinculin (green). (b) Quantification of the percentage of HUVECs displaying absence of
actin stress fibers in each condition. ***P < 0.001 (one-way ANOVA between groups P <
0.001; post-hoc multiple comparisons, Tukeyʼs test, n=60 cells per condition). (c)
Quantification of the percentage HUVECs with loss of actin stress fibers after Nrp1 or
control siRNA transfection incubated with Sema3d, Sema3e, or vehicle control. ***P <
0.001 (one-way ANOVA between groups P < 0.001; post-hoc multiple comparisons,
Tukeyʼs test, n=60 cells per condition), and Western blot of Nrp1 protein expression in
HUVECs after siRNA mediated knockdown. (d) Photomicrographs of HUVECs after
Nrp1 or control siRNA-mediated knockdown, seeded in Matrigel, and incubated with
Sema3d, Sema3e, or vehicle control for 8 hours. (e) Quantification of the number of
tubules formed per high power field. ***P < 0.001 (one-way ANOVA between groups P <
0.001; post-hoc multiple comparisons, Tukeyʼs test, n =9). Scale bar = 5 µm (a), 1 mm
(d).
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Figure 3.5 Sema3d signals through PI3K/Akt to repel endothelial cells via actin
cytoskeletal reorganization.
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Figure 3.5: Sema3d signals through PI3K/Akt to repel endothelial cells via actin
cytoskeletal reorganization.
(a) Western blot for phospho-Akt (S473) of HUVECs treated with Sema3d, Sema3e, or
vehicle for 5 minutes. (b) Quantification of Akt phosphorylation normalized to total Akt of
HUVECs incubated with 10nM of Sema3d, Sema3e, or a vehicle control for 5 minutes.
**P < 0.01, ns = not significant (one-way ANOVA between groups P < 0.01; post-hoc
multiple comparisons, Tukeyʼs test, n = 3). (c) Western blot for phospho-Akt (S473) of
HUVECs treated with increasing doses of Sema3d for 30 minutes. (d; top) Graph
representing the percentage of HUVECs that migrated through a porous transwell insert
in the presence of Sema3d or Sema3e compared with vehicle control. ***P < 0.001 (oneway ANOVA between groups P < 0.001; post-hoc multiple comparisons, Tukeyʼs test, n
= 3). (d; bottom) Graph representing the percentage of HUVECs that migrated through
a porous transwell insert towards media containing Wortmannin and either Sema3d or
Sema3e compared with vehicle control. *P < 0.05, ns = not significant (one-way ANOVA
between groups P < 0.001; post-hoc multiple comparisons, Tukeyʼs test, n = 3). (e)
HUVECs were incubated with Sema3d, Sema3e, or vehicle control with or without
Wortmannin (1 μM) for 30 min and subsequently stained for F-actin (red) and vinculin
(green). (f) Quantification of the percentage of HUVECs displaying absence of actin
stress fibers in each condition. ***P < 0.001 (one-way ANOVA between groups P <
0.001; post-hoc multiple comparisons, Tukeyʼs test, n=60 cells per condition). Scale bar
= 5 µm.
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Chapter 4 : Endothelial ErbB2 as a semaphorin receptor in coronary
development

Summary

Recent work has elucidated the cellular origins and molecular mechanisms that
contribute to coronary vasculogenesis. However, little is known about how coronary
vessels ultimately form arterial and venous connections to the circulatory system.
Semaphorin 3d (Sema3d) is a secreted guidance molecule that is required for proper
connections of the pulmonary veins to the developing heart, but the receptor for Sema3d
that mediates vascular patterning has not been defined. Although most secreted
semaphorins bind to heterodimers of neuropilins and plexins, neuropilins can also
interact with a variety of other partners to form functional receptors. Here, we show that
Sema3d is necessary during embryogenesis not only for pulmonary vein development
but also for proper connections of the coronary veins to the right side of the heart. We
show, surprisingly, that ErbB2 is expressed by endothelial cells and can interact with
neuropilin 1 (Nrp1) to form a functional Sema3d receptor to mediate repulsive guidance
cues necessary for proper patterning of the coronary veins. These findings have
implications for possible cardiovascular side-effects of anti-ErbB2 therapies and suggest
new targets for pro- and anti-angiogenic strategies.

Introduction
	
  
Early in mammalian development, circulating blood within the heart chambers is
sufficient to provide oxygen and nutrients to the surrounding myocardium through simple
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diffusion. As the embryo grows, increased demand is placed on the heart to pump blood
to the body, and the myocardium thickens. The coronary vasculature develops to supply
myocardial cells that can no longer be nutritionally sustained by simple diffusion from the
cardiac lumen. Congenital abnormalities in coronary development can lead to
pathologies such as myocardial ischemia, malignant arrhythmias, and sudden death
(Angelini 2007).

Blood vessels are patterned either by vasculogenesis, angiogenesis or a combination of
the two processes. Vasculogenesis is the formation of blood vessels de novo from
endothelial cells, while angiogenesis refers to the sprouting of new vessels from existing
vessels. Until the late 1980s, it was believed that the coronary arteries and veins arose
through angiogenesis from their points of origin, the aorta and coronary sinus
respectively (Hutchins, Kessler-Hanna et al. 1988). That notion was challenged when it
was shown that the coronary vasculature is present in the heart well before there are
connections to the circulation (Bogers, Gittenberger-de Groot et al. 1989). Recently, a
number of studies have identified various sources of the endothelial cells that give rise to
the coronary arterial and venous vasculature including the proepicardium (Katz, Singh et
al. 2012), epicardium, endocardium, and sinus venosus (Red-Horse, Ueno et al. 2010;
Chen, Sharma et al. 2014). Cells migrating from these sources form tubular structures
and a primary vascular plexus surrounding the heart. During this time, the arterial
vascular tubes around the aortic trunk penetrate the aorta, while the venous capillary
beds form connections with the coronary sinus allowing for circulation of blood through
the coronary vessels. The coronary arteries receive oxygenated blood from the aorta
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and the coronary veins return deoxygenated blood to the coronary sinus, which drains
into the right atrium.

Recent studies have revealed some clues to the cellular and molecular mechanisms
required for coronary arterial connection to the aorta. Neural crest ablation in chick is
associated with anomalous origins of the coronary arteries (Hood and Rosenquist 1992),
and Vegf family ligands are necessary for coronary artery penetration into the aortic root
(Tomanek, Ishii et al. 2006). However, very little, if anything, is known about the
mechanisms mediating coronary venous connections.

Class 3 semaphorins (Sema3) compose a family of secreted ligands that have been
shown to be important guidance molecules in cardiovascular development and vascular
patterning (Epstein, Aghajanian et al. 2015) in addition to their role in guiding neuronal
path-finding (Dickson 2002). Sema3c deficient mice die perinatally from persistent
truncus arteriosus and interrupted aortic arch (Feiner, Webber et al. 2001), Sema3e
disruption leads to a loss of patterning of intersomitic vessels (Gu, Yoshida et al. 2005),
and Sema3d null mice develop total anomalous pulmonary venous connections
(TAPVC)(Degenhardt, Singh et al. 2013). Although Sema3e can bind to and signal via
plexin D1 alone (Gu, Yoshida et al. 2005), most Sema3 proteins require the co-receptor
neuropilin 1 (Nrp1) or neuropilin 2 to bind in conjunction with a signaling receptor such
as a plexin (Takahashi, Fournier et al. 1999). Neuropilins are also known to
heterodimerize with various related tyrosine kinase receptors such as Vegfr2
(KDR)(Soker, Miao et al. 2002).
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Erb-b2 receptor tyrosine kinase 2 (ErbB2) is a member of the epidermal growth factor
(EGF) receptor family. ErbB2 is unique among EGF receptors in that it has no known
direct ligand and generally functions as a co-receptor (Klapper, Glathe et al. 1999).
Though ErbB2 expression is well characterized in myocardium (Wadugu and Kuhn
2012) and plays a critical role in cardiac development (Crone, Zhao et al. 2002; Ozcelik,
Erdmann et al. 2002), a role in endothelial function has yet to be described.

In this chapter I demonstrate that Sema3d in the mouse is required for proper
connections of the forming coronary veins to the right atrium and we provide evidence
that it repels venous coronary endothelial cells during development to prevent
anomalous venous connections to the left atrium. I show that ErbB2 interacts with Nrp1
to form a Sema3d co-receptor expressed by developing coronary endothelium. Thus,
ErbB2 plays an unexpected and important role in the vasculature.

Results
Abnormal coronary venous connections in Sema3d null mice
We examined the hearts of postnatal Sema3d-/- mice to investigate the effects of
Sema3d on the development of the coronary vasculature. Unlike human, murine
coronary vessels reside in two distinct anatomical compartments. The coronary veins
are subepicardial and are visible on the heart surface, while the coronary arteries are
intramyocardial and cannot be visualized upon gross inspection. Surface vessels, the
presumptive coronary veins, are seen abnormally connecting to the left atrium in
Sema3d-/- adult hearts, but not in Sema3d+/- controls (Figure 4.1a). To better visualize
the coronary vessels and connections, we perfused the vasculature with a low viscosity
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compound (Microfil) and observed that ~30% of the Sema3d-/- hearts (8/27) displayed
abnormal connections of the anterior interventricular vein (AIV) to the left atrium, while
none (0/36) of the Sema3d+/- controls exhibited this abnormal connection (Figure 4.1b).

To verify the arterial/venous identities of the coronary vessels, we crossed the Sema3d+/mice with either an arterial (ephrin-B2LacZ) or venous (Ephb4LacZ) endothelial reporter.
Whole-mount X-gal staining of Sema3d-/-;Ephb4LacZ/+ hearts shows Ephb4 positive
vessels abnormally connecting to the left atrium (Figure 4.1c, arrow). These
connections are absent in the Sema3d+/-;Ephb4LacZ/+ controls (Figure 4.1c). Arterial
Microfil perfusion reveals normal origins of the coronary arteries in both Sema3d null and
control hearts (Figure 4.1d). X-gal staining of Sema3d+/-;ephrin-B2LacZ/+ and Sema3d-/;ephrin-B2LacZ/+ hearts confirms the arterial identity of these coronary vessels (Figure
4.1e). These data suggest that Sema3d specifically affects the connections of the
coronary veins and not coronary arteries.

We examined hearts from a developmental series of Sema3d-/-;Ephb4LacZ/+ and Sema3d/-

;ephrin-B2LacZ/+ embryos, and litter mate controls, to determine if the initial formation of

coronary vessels was perturbed. These experiments indicate that emergence of Ephb4+
venous coronary endothelium and assembly of the primitive vascular plexus that
matures into the coronary venous system is unaffected by the absence of Sema3d, and
the first reproducible defect that we observed was an abnormal connection to the left
atrium evident by E15.5 (Figure 4.2). No clear abnormalities of arterial endothelial
specification, plexus formation or connections with the aorta were identified (Figure 4.3).
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In order to further examine the nature of the abnormal venous connections, we
examined serial H&E stained sections, which confirmed the existence of an abnormal
coronary vascular connection to the left atrium in Sema3d-/- hearts. The abnormal vessel
is superficial, consistent with venous identity, and traverses the left anterior
atrioventricular (AV) groove before emptying into the left atrial lumen (Figure 4.1f). X-gal
and eosin stained serial sections from a Sema3d-/-;Ephb4LacZ/+ heart confirm the venous
identity of this mis-patterned vessel (Figure 4.1g).

Sema3d expression restricts coronary endothelium
We further examined venous endothelial patterning at E15.5 when vascular defects were
first detected in the Sema3d null hearts. X-gal staining of E15.5 Sema3d+/-;Ephb4LacZ/+
heart sections reveals little to no venous endothelium in the left anterior AV groove
(Figure 4.4a). This is in contrast to numerous LacZ positive venous endothelial cells
seen traversing this junction and in close association with the left atrium in Sema3d-/;Ephb4LacZ/+ embryonic hearts (Figure 4.4b). Examination of Sema3dGFPCre/+ hearts,
which have GFP knocked into the Sema3d locus resulting in a null allele(Katz, Singh et
al. 2012; Degenhardt, Singh et al. 2013), reveals that Sema3d is expressed within the
left anterior AV groove (Figure 4.4c, arrow). In control embryos, this area of Sema3d
expression is relatively avascular compared with the surrounding myocardium as
determined by a lack of eNOS expression (Figure 4.4c). GFP is similarly expressed in
the left anterior AV groove of the Sema3dGFPCre/GFPCre null hearts (Figure 4.4c, arrow),
and lineage-tracing Sema3d expressing cells gives rise to a similar pattern of cells
populating the AV groove in Sema3d null and control hearts (Figure 4.5). But unlike the
controls, numerous eNOS positive vessels are seen penetrating this previously
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avascular zone in Sema3dGFPCre/GFPCre (Figure 4.4d). Given the ability of Sema3d to
function as an endothelial repellent (Aghajanian, Choi et al. 2014), we interpret these
findings to suggest that Sema3d forms a barrier to restrict venous endothelial cells from
populating the left anterior AV groove thereby preventing aberrant connections with the
left atrium (Figure 4.4e).

ErbB2 is a co-receptor for Sema3d
Sema3d binds to and requires Nrp1 for signaling to endothelial cells (Degenhardt, Singh
et al. 2013; Aghajanian, Choi et al. 2014), but a signaling co-receptor for Sema3d has
yet to be fully described. To discover the endothelial signaling co-receptor for Sema3d
we conducted a receptor tyrosine kinase screen (see methods) and identified ErbB2 as a
potential Sema3d co-receptor. ErbB2 is phosphorylated in response to Sema3d in
human umbilical vein endothelial cells (HUVECs) in a dose dependent manner (Figure
4.6a). To determine the requirement of ErbB2 in Sema3d mediated endothelial guidance
we employed a transwell migration assay. Both Sema3d and Sema3e are able to inhibit
the migration of endothelial cells through a porous membrane (Figure 4.6b). Knockdown
of ErbB2 specifically abrogates the ability of Sema3d, but not Sema3e, to inhibit
endothelial migration (Figure 4.6b). We previously demonstrated Sema3d dependent
phosphorylation of Akt and the requirement of PI3K/Akt signaling in Sema3d mediated
endothelial guidance (Aghajanian, Choi et al. 2014). Akt and ErbB2 phosphorylation in
response to Sema3d are both evident within 5 minutes of incubation (Figure 4.6c).
siRNA knockdown of ErbB2 in HUVECs abrogates Sema3d-induced Akt phosphorylation
(Figure 4.6d, e), indicating that ErbB2 is necessary for downstream repellent signaling
mediated by Sema3d in HUVECs.
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ErbB2 is expressed by coronary venous endothelial cells
If ErbB2 is directly participating in Sema3d-mediated receptor signaling during coronary
vein development, we predicted that it would be expressed by nascent coronary venous
endothelium just prior to the time when abnormal venous connections are seen in
Sema3d mutant embryos. At E14.5, shortly before anomalous venous connections are
observed in Sema3d null hearts, eNOS-positive endothelial tubes co-express ErbB2
(Figure 4.7a). Myocardial ErbB2 expression is also evident, consistent with previous
observations of ErbB2 expression by cardiac muscle at earlier embryonic time-points
(Lee, Simon et al. 1995) (Figure 4.7a). Expression of ErbB2 by coronary venous
endothelium persists through at least E17.5 and is largely restricted in the heart to
subepicardial (venous) endothelial cells (Figure 4.7b, Figure 4.8, white arrowheads)
and not intra-myocardial (arterial) coronary vessels (Figure 4.7b, Figure 4.8, yellow
arrowheads). At E14.5, Y1248 phosphorylation of ErbB2 is detected by
immunofluorescence in coronary endothelium of Sema3d+/- hearts, consistent with
receptor activation (Figure 4.7c). However, phospho-ErbB2 is not detected in coronary
endothelium of Sema3d-/- hearts (Figure 4.7c). Importantly, genetic deletion of ErbB2 in
endothelium during development, using Tie2-Cre, recapitulates the anomalous
pulmonary venous connection (APVC) phenotype previously described in Sema3d-/mice (Degenhardt, Singh et al. 2013)(Figure 4.9). Moreover, endothelial deletion of
ErbB2 results in the anomalous coronary venous connection to the left atrium described
here in Sema3d-/- mice (Figure 4.7d), providing strong genetic evidence for ErbB2
functioning in a signaling pathway with Sema3d.
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ErbB2 and Nrp1 form a Sema3d holoreceptor
To test whether Sema3d is capable of directly binding to ErbB2, we performed binding
experiments using an alkaline phosphatase (AP) tagged Sema3d (Sema3d-AP).
Sema3d-AP does not bind to Cos-7 cells expressing ErbB2, but does bind to Nrp1
expressing cells (Figure 4.10a). Co-expression of ErbB2 with Nrp1 does not increase
the binding of Sema3d-AP over that seen with Nrp1 alone, suggesting that Nrp1 may
serve to bind Sema3d while ErbB2 may participate in signal transduction (Figure 4.10a,
Figure 4.11). Co-immunoprecipitation experiments indicate that ErbB2 and Nrp1 can
physically interact in the presence or absence of Sema3d (Figure 4.10b). This
interaction is validated by a proximity ligation assay, in which ErbB2 and Nrp1 are shown
to be in close physical proximity (<40 nm) when co-transfected in 293T cells (Fig 4.12).
Deletion of the extracellular domain of ErbB2 abolishes the interaction with Nrp1, while
deletion of the intracellular domain of ErbB2 does not (Figure 4.10c). Serial truncations
of the ErbB2 extracellular domain maps the Nrp1 interaction proximal to the
transmembrane domain (Figure 4.13).

siRNA-mediated knockdown of Nrp1 in HUVECs prevents ErbB2 receptor
phosphorylation in response to Sema3d (Figure 4.10d), and ErbB2 and Nrp1 co-localize
in coronary vessels of the developing heart (Figure 4.10e). Taken together, these data
support the hypothesis that ErbB2 and Nrp1 heterodimerize to form a functional Sema3d
holoreceptor.
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Discussion

In this study, we provide evidence for an unexpected role for ErbB2 in venous
endothelial cells where it can partner with Nrp1 to form a receptor for the repellent
guidance molecule Sema3d (Figure 4.10f). To the best of our knowledge, a functional
role for ErbB2 in endothelium has not been previously reported, and these findings raise
the possibility that vascular effects could arise from pharmacologic or other therapeutic
approaches targeting ErbB2.

ErbB2 is known to partner with various co-receptors including the epidermal growth
factor receptor (EGFR), ErbB3 and ErbB4 (Tzahar, Waterman et al. 1996). Interestingly,
ErbB2 has been previously implicated in semaphorin signaling. Certain class 4
semaphorins involve ErbB2 in axonal growth cone collapse (Swiercz, Worzfeld et al.
2009) or mitotic spindle orientation (Xia, Swiercz et al. 2015). A cleaved, oncogenic
isoform of Sema3e signals through ErbB2 to promote metastasis (Casazza, Kigel et al.
2012). In these examples, signaling requires a plexin in the receptor complex; plexin B1
in the case of Sema4 proteins and plexin D1 in the case of Sema3e. A functional
interaction between ErbB2 and Nrp1 has not been previously reported.

In the heart, ErbB2 has been shown to play a critical role in development of the
myocardium and has been implicated in control of cardiomyocyte proliferation (D'Uva,
Aharonov et al. 2015) and as a potential target for regenerative therapies (Polizzotti,
Ganapathy et al. 2015). Genetic deletion of ErbB2 in cardiomyocytes during
development results in dilated cardiomyopathy (Crone, Zhao et al. 2002; Ozcelik,
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Erdmann et al. 2002). Anticancer drugs targeting ErbB2 can lead to heart failure
(Sengupta, Northfelt et al. 2008), presumably through cardiotoxicity. The coronary
endothelial expression of ErbB2 that we describe here suggests an alternative
mechanism to explain the cardiotoxic effects of such therapies. Perhaps inhibition of
ErbB2 in endothelial cells results in endothelial dysfunction and secondary myocardial
dysfunction. Further investigation of the role of ErbB2 in adult coronary endothelium will
be required to address this hypothesis.

Our results indicate that Sema3d is necessary for proper coronary venous connections
in the developing heart, but is dispensable for coronary arterial connections. While there
is evidence of the molecular determinants of coronary venous origin and development
(Arita, Nakaoka et al. 2014), far less is known about the mechanisms of coronary venous
connections. Based on the expression pattern of Sema3d, aberrant endothelial cell
localization in Sema3d nulls, and the known repellent properties of Sema3d on
endothelium, we propose that Sema3d expression in the left AV groove functions as a
repellent barrier to prevent the developing coronary veins from aberrantly connecting to
the left atrium.

The clinical implications of abnormal venous patterning are generally less significant
than those related to aberrations of arterial patterning, and this may explain why
development of the coronary arteries has been more extensively studied than that of the
coronary veins. Nevertheless, numerous variations of human coronary vein anatomy
have been described (von Ludinghausen 1987; Loukas, Bilinsky et al. 2009) including
anomalous connections to the left atrium (Pizarro, Castillo et al. 2009) as seen in
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Sema3d null mice. The anatomy of the coronary veins is of clinical significance with
regard to cardiovascular interventions such as cardiac pacing, retrograde cardioplegia
during cardiopulmonary bypass (Ruengsakulrach and Buxton 2001), and interpretation
of cardiac catheterization studies. There has also been recent evidence that the
coronary veins instruct sympathetic innervation in the developing heart (Nam, Onitsuka
et al. 2013).

Materials and Methods

Mice:
All mice were maintained on a mixed genetic background. Sema3dGFPCre, Tie2-Cre, and
R26Tomato alleles have been previously described (Kisanuki, Hammer et al. 2001;
Madisen, Zwingman et al. 2010; Degenhardt, Singh et al. 2013). Ephb4LacZ/+ and ephrinB2LacZ/+ mice were obtained from the laboratory of Yoh-suke Mukouyama (NIH).
ErbB2fl/LacZ hearts were obtained from the laboratory of Dr. Eldad Tzahor(Britsch, Li et al.
1998; D'Uva, Aharonov et al. 2015) (Weizmann Institute of science). All animal protocols
were approved by the University of Pennsylvania Institutional Animal Care and Use
Committee (IACUC).

Reagents and antibodies:
Human recombinant Sema3e (#3239-S3-025), human recombinant Sema3d were
obtained from R&D Systems. Anti-phospho- Akt (#4060), anti-Akt (#9272), anti-β-actin
(#4967), anti-ErbB2 (#4290), and anti-phospho-ErbB2 (#2247) were purchased from Cell
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Signaling, along with anti-Nrp (Santa Cruz, #7239), anti-V5 (Life technologies, #R960),
anti-ENOS (BD Biosciences, #610296), and anti-GFP (Abcam, #AB6673). Lipofectamine
2000 (Invitrogen) was used as the transfection reagent for HEK293T and Cos-7 cells.
Lipofectamine RNAiMAX (Invitrogen, 13778030) was used for siRNA transfections.

Histology, immunohistochemistry, and whole-mount staining:
Samples were harvested, fixed overnight in 2-4% paraformaldehyde and dehydrated
through an ethanol series. All samples were paraffin-embedded and sectioned.
Antibodies used for immunofluorescence were anti-ErbB2 (Cell Signaling), anti-phoshpoErbB2 Y1248 (Cell Signaling), anti-Nrp1 (Santa Cruz), anti-GFP (Abcam), and antieNOS (BD Biosciences). Hematoxylin and eosin (H&E) staining was completed using a
standard protocol.

For whole mount X-gal staining, adult and embryonic hearts were isolated and fixed with
2% paraformaldehyde in PBS for 20 minutes at 4°C. Following fixation, the samples
were washed twice for 10 minutes in PBS at 4°C. Embryos were stained in with PBS
containing 1 mg/ml X-gal, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2 mM MgCl2, 0.01% NP40, 0.01% sodium deoxycholate and incubated overnight at 37 °C.

Cell culture:
Cos-7 and HEK293T cells were cultured in Dubeccoʼs modified Eagleʼs media (DMEM)
from Sigma with 10% fetal bovine serum (FBS). Primary human umbilical vascular
endothelial cells (HUVECs) (lot #1023) were cultured in human endothelial cell culture
media, VascuLife® EnGS (#LL-0002) (basal EnGS media, 0.2% EnGS, 5 ng/ml rh EGF,
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50 µg/ml ascorbic acid, 10 mM L-glutamine, 1.0 µg/ml hydrocortisone hemisuccinate,
0.75 U/ml heparin sulfate and 2%) from Lifeline Cell Technology.

Microfil:
Mice were sacrificed at 2-3 weeks of age to evaluate the coronary artery and vein
morphology. Mice were euthanized by CO2 inhalation, and the thoracic cavity was
opened surgically. The large branches from the aorta were ligated. The vasculature was
flushed with normal saline containing heparin (200 U/ml) via a needle inserted into the
descending aorta until heart became visibly blanched. The heart was then pressure-fixed
with 2% paraformaldehyde. Paraformaldehyde was flushed from the heart in heparinized
saline, and coronary vasculature was injected with a radiopaque silicone rubber
compound (Microfil MV-122; Flow Tech, Carver, MA) solution prepared in a volume ratio
of 1:1 of Microfil diluent with 5% curing agent. Once filling is complete, to prevent
the Microfil leakage from the coronary vessels, the accessible major vascular exit points
were ligated immediately after filling. Heart was stored at 4 °C for contrast agent
polymerization.

Transwell migration assay:
Triplicate transwell inserts (BD Biosciences, 353097) were coated on the underside with
10µg/ml fibronectin (Roche, 11051407001) and placed in individual wells of a 24 well
plate containing either 10nM recombinant Sema3d or vehicle (PBS) in DMEM.
Endothelial cells treated with either an ErbB2 or control siRNA were trypsinized, resuspended in DMEM containing 0.2% BSA (Gemini, 700-101P) Cells were counted and
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105 cells were seeded in each insert and allowed to migrate for 5 hours. The migrated
cells were fixed in 4% paraformaldehyde for 2 mins, permeabilized in methanol for 20
mins, and giemsa (Sigma, GS-500) stained for 25 mins. Cell that did not migrate were
cleaned out from the inside of the insert with a cotton swab. Three high-power fields of
each insert were imaged using an Olympus MVX10 microscope and quantified using
ImageJ.

Alkaline phosphatase binding assay:
Alkaline phosphatase tagged Sema3d-AP (APtag5-Sema3d) was transfected into
HEK293T cells to produce conditioned media. Sema3d-AP binding to transfected Cos7
cells (YFP, plexin D1, Nrp1, ErbB2) was conducted as previously described(Gitler, Lu et
al. 2004). Binding was visualized and recorded on an Olympus MVX10 microscope.
Photomicrographs were analyzed and quantified using ImageJ software.

Immunoprecipitation and Western blotting:
Immunoprecipitation was performed by transfecting HEK293T cells with Nrp1 and/or
ErbB2-V5, or truncated ErbB2 constructs. 48 hrs after transfection, cells were lysed with
IP lysis buffer (50 mM Tris-HCl; 150 mM NaCl, 1% Ipegal (v/v)), and sonicated on ice.
The cell lysates were precleared with protein-G dynabeads (Life technologies, #10004D)
for 1 hr at 4°C. Precleared lysates were rotated with either 2 µg of Nrp1 antibody, or 2 µg
of normal goat IgG (Santa Cruz, #2028) for 2 hrs at 4°C. Protein-G dynabeads were
added and rotated overnight at 4°C. Beads were washed 3 times in IP wash solution (25
mM Tris-HCl; 150 mM NaCl), eluted in sample buffer (Life technologies, #NP0007;
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100nM DTT, 10% 2-mercaptoethanol), and run on a 4-12% Bis-Tris gradient gel (Life
technologies, #NP0336). Gels were transferred to PVDF (Life technologies, #LC2002)
and blocked according to antibody manufacturerʼs instructions.

Blots were probed with anti-ErbB2 (1:1000), anti-phospho-ErbB2 (1:1000) anti-phosphoAkt (1:2000), anti-Akt (1:1000), anti-β-actin (1:1000), anti-V5 (1:5000), or anti Nrp1
(1:1000) as per manufacturerʼs instructions. Visualization was achieved using ECL Prime
(GE Life Sciences, #RPN2232) exposed to autoradiography film (Denville, #E3018).
Quantification of individual band intensity was performed using ImageJ.

ErbB2 truncations:
Truncations were made to the plasmid ErbB2-pEF-Dest51 using site directed
mutagenesis PCR. PfuUltra high-fidelity DNA polymerase (Agilent, 600380) was used to
amplify a plasmid with 5ʼ phosphorylated primers flanking the regions to be deleted
(Primers available upon request). Linear PCR products were circularized using T4 DNA
ligase (Invitrogen, 15224) and sequenced.

RNA interference:
HUVECs were transfected with Lipofectamine RNAiMAX (Invitrogen, 13778030) using
ErbB2 siRNA (Cell Signaling), Nrp1 pre-designed siRNA (Ambion, #4914) or Silencer
Negative control siRNA #1 (Ambion, AM4611) in antibiotic-free media. The media was
changed to complete HUVEC media after 24 hrs, and the cells were used at 48 hrs.

Proximity ligation assay:
	
  
	
  

	
  

120	
   	
  

	
  

HEK293T cells were grown in chamber slides (BD Falcon, Franklin Lakes, NJ) and
transfected with 40ng of cDNA for ErbB2-V5 and/or WT Nrp1. All wells were incubated
with a combination of anti-V5 (1:200) and anti-Nrp1 (1:200) primary antibodies for 1
hour. Fluorescent visualization of interactions was performed using the Duolink® In Situ
Detection Reagents- Red kit (Sigma-Aldrich, St. Louis, MO) following manufacturer's
instructions. The Duolink® mounting media used includes DAPI nuclear stain.

Receptor tyrosine kinase array:
Receptor screening was performed using Proteome Profiler™ Human Phospho-RTK
Array Kit (R&D Systems, ARY001B) per manufacturerʼs instructions. Briefly, HUVECs
were incubated with either 10nM Sema3d or a PBS vehicle control for 30 minutes. Cells
were washed and lysates were made using included lysis buffer plus protease inhibitors.
The provided membranes were incubated with Sema3d treated and control cell lysates
overnight at 4°C and probed with the provided Anti-Phospho-Tyrosine-HRP Detection
Antibody. Membranes were incubated with a provided chemiluminescent reagent and
exposed to autoradiography film (Denville, #E3018). Quantification of dot intensity was
performed with ImageJ software.

Statistics:
All data are represented as the mean ± standard error of the mean (SEM). Two sets of
data were compared using Studentʼs t-test. Differences between groups were compared
with one-way analysis of variance (ANOVA). Significant ANOVA results were further
analyzed by Tukeyʼs multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ns =
not significant.
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Figure 4.1 Coronary veins abnormally connect to the left atrium in Sema3d-/hearts
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Figure 4.1 Coronary veins abnormally connect to the left atrium in Sema3d-/hearts.
(a) Left anterior oblique view of adult Sema3d+/– (top) and Sema3d–/– (bottom) hearts.
The anterior interventricular vein (arrow) can be seen connecting to the left atrium in the
Sema3d-/- heart. (b) Mircrofil perfusion of 3 week old hearts from Sema3d+/– (top) and
Sema3d–/– (bottom) mice. (c) Whole-mount X-gal staining of Sema3d+/-;Ephb4LacZ/+ (top)
and Sema3d-/-;Ephb4LacZ/+ (bottom) postnatal hearts. (d) Cleared Sema3d+/– (top) and
Sema3d–/– (bottom) postnatal hearts perfused with Microfil to visualize the origin of the
coronary arteries (arrowheads). (e) Whole mount X-gal staining of Sema3d+/-;ephrinB2LacZ/+ (top) and Sema3d-/-;ephrin-B2LacZ/+ (bottom) postnatal hearts verifying arterial
identity of the coronary vessels originating from the aorta (arrowheads). (f)
Photomicrographs of H&E stained frontal sections from a Sema3d-/- heart following a
coronary vein (arrows) from the left anterior AV groove connecting with the left atrial
lumen. (g) Photomicrographs of eosin and X-gal stained frontal sections from a postnatal
Sema3d-/-;Ephb4LacZ/+ heart following a coronary vein (arrows) from the left anterior AV
groove connecting with the left atrial lumen. LV, left ventricle; RV, right ventricle; LA, left
atrium; AO, aorta; PA, pulmonary artery. Scale bars = 100μm.
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Figure 4.2 Whole mount X-gal staining on a developmental time-course of hearts
from Sema3d+/-;Ephb4LacZ/+ and Sema3d-/-;Ephb4LacZ/+ embryos
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Figure 4.2 Whole mount X-gal staining on a developmental time-course of hearts
from Sema3d+/-;Ephb4LacZ/+ and Sema3d-/-;Ephb4LacZ/+ embryos.
In both the Sema3d nulls and controls, Ephb4 expression can be seen as early as E10.5
in the sinus venosus (a, j; arrows). Ephb4 positive endothelial cells are not seen (b-d, km) outside of the immediate area surrounding the sinus venosus until E14.5 when the
subepicardial endothelial cells re-specify to a venous identity, and are seen in both the
Sema3d null and control hearts beginning at E14.5 (e, n; inset, arrowheads). By E15.5
more mature venous vessels are present in the control and Sema3d null hearts (f, o;
inset, arrowheads), and can be seen near the left atrium (o; arrow, inset). One day
later (E16.5), the anomalous connections of the coronary veins are grossly
distinguishable in the nulls (p; arrow, inset) and continue to develop through gestation
(q, r; arrows), but are not seen in the controls (g-i). These data indicate that early in
development Sema3d null venous endothelial cells migrate and pattern appropriately but
by E15.5 incorrect venous connections begin to form. Scale bars = 100μm.
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Figure 4.3 Whole mount X-gal staining on a developmental time-course of hearts
from Sema3d+/-;ephrin-B2LacZ/+ and Sema3d-/-;ephrin-B2LacZ/+ embryos
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Figure 4.3 Whole mount X-gal staining on a developmental time-course of hearts from
Sema3d+/-;ephrin-B2LacZ/+ and Sema3d-/-;ephrin-B2LacZ/+ embryos. Ephrin-B2 positive
arterial endothelial cells are not detected (a-b, j-k) until E12.5 when a peritruncal
vascular plexus is seen (c, l; arrowheads, insets) in the Sema3d control and null
hearts. Arterial development continues normally in the Sema3d null and control hearts
(d-h, m-q) including the origins of the coronary arteries (i, r) at E18.5. Scale bars =
100μm.
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Figure 4.4 Sema3d expression excludes endothelium from the AV groove
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Figure 4.4 Sema3d expression excludes endothelium from the AV groove.
(a,b) X-gal and eosin staining of Sema3dGFPCre/+;Ephb4LacZ/+ (a) and
Sema3dGFPCre/GFPCre;Ephb4LacZ/+ (b) E15.5 heart frontal sections. Numerous LacZ positive
(venous) cells can be observed in the left anterior AV junction of the Sema3d nulls (b;
arrow) but not in the control (a). (c,d) Immunofluorescence for the endothelial marker
eNOS (red) and GFP (green) of E15.5 Sema3dGFPCre/+;Ephb4LacZ/+ (c) and
Sema3dGFPCre/GFPCre;Ephb4LacZ/+ (d) heart frontal sections. The GFP expressing left
anterior AV groove (arrow) is mostly avascular in the control (c) but penetrated by
numerous eNOS positive (red) vessels in the Sema3d null (d). (e) Model depicting the
role of Sema3d in coronary venous connection. In wild type mice, Sema3d is expressed
in the left anterior AV groove and repels venous endothelium from abnormally forming
connections with the left atrium (left), but in the absence of Sema3d the coronary
anterior interventricular vein (AIV) abnormally connects to the LV (right). LV, left
ventricle; RV, right ventricle; LA, left atrium; RA, right atrium. Scale bars = 100μm.
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Figure 4.5 Sema3d fate-maps to left anterior AV groove

	
  
	
  

	
  

130	
   	
  

	
  

Figure 4.5 Sema3d fate-maps to left anterior AV groove.
(a, b) Immunofluorescence for RFP (red) on frontal sections of E14.5 Sema3dGFPCre/+;
R26Tomato/+ (a) and Sema3dGFPCre/GFPCre; R26Tomato/+ (b) hearts. Sema3d expressing cells
similarly fatemap to the left anterior AV groove in both the control (a, outline) and null
(b, outline) hearts. LA = Left atrium, LV = Left ventricle. Scale bars = 100μm.
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Figure 4.6 Sema3d signals via ErbB2 in endothelial cells
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Figure 4.6 Sema3d signals via ErbB2 in endothelial cells.
(a) Western blot for phospho-ErbB2 (Y1248) from HUVECs incubated with increasing
concentrations of Sema3d for 30 minutes. (b) Transwell migration assay showing the
percentage HUVECs that migrated through a porous membrane in the presence of
Sema3d or Sema3e when compared to vehicle control in the presence of a control
siRNA (left) or ErbB2 siRNA (right). ***P < 0.001, *P < 0.05, ns = not significant (oneway ANOVA between groups P < 0.001 for both groups; post-hoc multiple comparisons,
Tukeyʼs test) (c) Western blot for phospho-Akt (S473) and phospho-ErbB2 (Y1248) from
HUVECs incubated with increasing concentrations of Sema3d for 5 minutes. (d) Western
blot for ErbB2 and phospho-Akt (S473) of HUVECs in the presence of control or ErbB2
siRNA treated with Sema3d (10nM) for 5 minutes. (e) Quantification of ErbB2
knockdown and Akt phosphorylation from (d). **P < 0.01, *P < 0.05 (Studentʼs t-test,
n=3)
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Figure 4.7 ErbB2 is expressed by coronary venous endothelium
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Figure 4.7 ErbB2 is expressed by coronary venous endothelium.
(a) Immunofluorescence of a frontal section of an E14.5 heart for the endothelial marker
eNOS (red) and ErbB2 (green). ErbB2 and eNOS co-localize to vessels in the
antrioventricular junction (arrowheads) (b) Frontal section of an E17.5 heart co-stained
for eNOS (red) and ErbB2 (green) demonstrating co-localization in subepicardial vessels
(white arrowheads) but not in intra-myocardial vessels (yellow arrowheads). (c)
Phospho-ErbB2 (Y1248) immunofluorescence from frontal sections of E14.5 Sema3d+/–
and Sema3d–/–hearts. ErbB2 phosphorylation is reduced in the Sema3d–/– hearts
(arrowheads) (d) Photomicrographs of H&E stained frontal sections from a postnatal
ErbB2fl/–;Tie2-Cre heart tracing a vessel from the left anterior AV groove to the left atrial
	
  

lumen (arrows). LV, left ventricle; LA, left atrium. Scale bars = 100μm.
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Figure 4.8 ErbB2 is specifically expressed in coronary venous endothelium
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Figure 4.8 ErbB2 is specifically expressed in coronary venous endothelium.
Immunofluorescence for the endothelial marker eNOS (red) and ErbB2 (green) on frontal
sections from E17.5 heats showing the left ventricular wall. Subepicardial vessels
(venous) are ErbB2 positive (yellow arrowheads), while deeper, myocardia vessels
(arterial) are negative for ErbB2. Scale bars = 100μm.
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Figure 4.9 ErbB2 endothelial loss results in APVC
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Figure 4.9 ErbB2 endothelial loss results in APVC.
(a-d) H&E stained cross sections of a postnatal ErbB2fl/-;Tie2-Cre heart. The pulmonary
veins (green arrowhead) abnormally connect to the right atrium (RA) (d) resulting in an
anomalous pulmonary connection (APVC). RA = Right atrium, LA = Left atrium, RV =
Right ventricle, LV = Left ventricle, AO = Aorta, PA = Pulmonary artery, CS = Coronary
sinus. Scale bars = 100μm.
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Figure 4.10 ErbB2 and Nrp1 interact to form a Sema3d receptor
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Figure 4.10 ErbB2 and Nrp1 interact to form a Sema3d receptor.
(a) Representative photomicrographs of Cos-7 cells expressing indicated receptors after
binding and enzymatic detection of alkaline phosphatase tagged Sema3d protein. (b)
Co-immunoprecipitation of Nrp1 and ErbB2 in the presence or absence of Sema3d
(10nM). (c) Graphical representation of ErbB2 deletion constructs (top). Coimmunoprecipitation of Nrp1 and either full length or truncated ErbB2. (d) Western blot
for phospho-ErbB2 (Y1248) from HUVECs treated with a Nrp1 or control siRNA, with or
without Sema3d for 5 minutes. (e) Immunofluorescence of E15.5 hearts shows that
ErbB2 (green) and Nrp1 (red) co-localize in coronary vessels. (f) Model for Sema3d
signaling to coronary endothelial cells. Sema3d binds to the Nrp1 subunit of a
Nrp1/ErbB2 complex on endothelial cells. This results in the phosphorylation and
activation of ErbB2 and subsequent downstream signaling, including phosphorylation of
Akt. ECD = extracellular domain, TM = transmembrane domain, ICD = intracellular
domain. Scale bars = 10μm.
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Figure 4.11 Quantification of Sema3d binding
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Figure 4.11 Quantification of Sema3d binding.
Quantification of the relative integrated density of Cos-7 cells expressing either a YPF
control, plexin D1, ErbB2, Nrp1, or ErbB2 and Nrp1 bound with alkaline phosphatase
(AP) tagged Sema3d (Sema3d-AP) and developed using an AP colorimetric assay. ***P
< 0.001, ns = not significant. (one-way ANOVA between groups P < 0.001; post-hoc
multiple comparisons, Tukeyʼs test)

	
  
	
  

	
  

143	
   	
  

	
  

Figure 4.12 ErbB2 and Nrp1 are expressed in close proximity
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Figure 4.12 ErbB2 and Nrp1 are expressed in close proximity.
Duolink proximity ligation assay (PLA) of 293T cells transfected with ErbB2-V5, Nrp1, or
both. Red signal indicates physical proximity of proteins (<40 nm) and can be seen in the
cells that were co-transfected with ErbB2-V5 and Nrp1 (arrowheads), but not in the
controls. All conditions were incubated with anti-V5 and anti-Nrp1 antibodies. Scale bars
= 100μm.
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Figure 4.13 Graphical representation of ErbB2 truncations
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Figure 4.13 Graphical representation of ErbB2 truncations.
Co-immunoprecipitation of Nrp1 with either a full length (ErbB2-V5), progressive ErbB2
extracellular truncation (T1-T3), or complete extracellular truncation (ErbB2-V5 ΔECD)
protein. The shortest truncation of ErbB2 (T3) still interacts with Nrp1, while a complete
loss of the extracellular domain completely abrogates this interaction.

	
  
	
  

	
  

147	
   	
  

	
  

Chapter 5 : Conclusions, Ongoing Work, and Future Directions

Summary

In this dissertation I explore the complex signaling molecules and pathways involved in
patterning the vascular during development and how improper vascular patterning
results in congenital heart defects. Deciphering the causes and mechanisms of
congenital heart defects is a critical step in the process of one day developing novel
therapies and cures.

Chapter 2 began with the novel observation that mice null for Sema3d develop
anomalous pulmonary venous connections (APVC). Using these mice as a model and
tool to investigate APVC, we were able to demonstrate that the conventional
assumptions regarding the etiology and morphogenesis of this disorder were incorrect
and proposed a new way in which we believe APVC comes about. The role of Sema3d
in this process is one of a repellent guidance molecule for endothelial cells that restricts
the nascent pulmonary vein from forming abnormal connections. Sema3d binds and
signals through the co-receptor neuropilin 1 to repel endothelial cells. Luckily we were
able to obtain samples from and sequence the genome from patients with APVC and
found at least 1 variant of Sema3d that had decreased binding and repellent activity in
vitro, further suggesting an association.

Continuing the investigations of the Sema3d mediated endothelial guidance that we
observed in the work from Chapter 2; in Chapter 3 I explored the molecular cellular
	
  
	
  

	
  

148	
   	
  

	
  

effects of Sema3d on endothelial cells and compared and contrasted it with the class 3
semaphorin Sema3e. Both Sema3d and Sema3e inhibit cell adhesion, motility, and
migration by causing cytoskeletal reorganization. However, these effects are mediated
by distinct molecular processes. Sema3e but not Sema3d requires the receptor plexin
D1, while Sema3d but not Sema3e requires neuropilin 1. We find an additional molecular
component in Sema3d signaling in that Sema3d requires PI3K/Akt signaling to exert its
effects on endothelial cells. This is not the case with Sema3e.

My work for Chapter 4 began with my ongoing pursuit to discover the signaling receptor
for Sema3d. Through a receptor tyrosine kinase screen I found the RTK ErbB2 to be a
possible receptor for Sema3d. We find that ErbB2 is phosphorylated by Sema3d
incubation and required for Sema3d mediate repulsion of endothelial cells. Additionally
ErbB2 is required for the Sema3d mediated Akt phosphorylation that I described in
Chapter 3. In this investigation we found a second venous phenotype of the Sema3d
nulls, abnormal connections of the coronary veins to the left atrium. Interestingly, we
found that not only is ErbB2 expressed in the developing coronary vasculature, but
conditional inactivation of ErbB2 in endothelial cells recapitulates the abnormal coronary
venous phenotype of the Sema3d nulls and, strikingly, the APVC phenotype I described
in Chapter 2. ErbB2 forms a complex with the co-receptor neuropilin 1, that I described
in Chapters 2 and 3, to form a functional holoreceptor for Sema3d.

In the next sections I will describe some of the ongoing projects that have come from
investigating Sema3d and congenital heart defects, and also interesting future directions
for pursuit.
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Ongoing Work

Endothelial Pdgfra
In trying to dissect the signaling pathways necessary for Sema3d to properly pattern the
vasculature, one of my main puzzles was discovering the signaling receptor or receptors
involved. As I mentioned in the introductory chapter, I had hypothesized that platelet
derived growth factor alpha (Pdgfra) was the signaling receptor for Semaphorin 3d. This
was based on the genetic and animal model evidence showing an association of Pdgfra
and the congenital heart disease total anomalous pulmonary venous connection
(TAPVC), which we see in Sema3d null mice. Furthermore, our early experiments,
outlined in Chapter 2, suggested that Sema3d was signaling directly to the developing
endothelium and as such would require receptors on these endothelial cells to receive
said signal.

Pdgfra has been described in various cell types of the developing heart including cardiac
neural crest, cardiomyocytes, smooth muscle, and epicardial cells. Surprisingly, Pdgfra
expression had not been described in developing or adult endothelial cells. To
investigate Pdgfra expression in the developing vasculature, I performed flow cytometry
on cells from E11.5 Pdgfra-GFP embryos that were co-labeled with fluorescently
conjugated antibodies against Pecam1 (an endothelial marker) and GFP. Based on the
analysis from the flow cytometry, Pdgfra is expressed in up to 10% of the endothelial
cells of the developing embryo (Figure 5.1). Once it was established that Pdgfra was
expressed in embryonic endothelial cells, I sought to test the hypothesis that Pdgfra was
a receptor for Sema3d in developing endothelium. To test this, I used genetic tools to
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inactivate Pdgfra in endothelial cells. This was achieved this by crossing a Pdgfra floxed
allele with a Tie2Cre to create a conditional inactivation of Pdgfra. Conditional
inactivation of Pdgfra in the endothelium results in partial embryonic lethality (Table 5.1).
Of the ones that made it to birth (2/90), none had anomalous pulmonary venous
connections (data not shown). Furthermore, 7 additional mid-gestation Pdgfrafl/fl;Tie2-Cre
embryos had normal connections of the pulmonary veins. These mutants displayed
subtle cardiovascular abnormalities (hemorrhage, stenosis, clots), but no major heart
defects were noted.

To try to enhance the penetrance of an effect, we crossed the Pdgfra-flox allele onto a
Pdgfra-null background to achieve haploinsufficiency. While Pdgfrafl/fl;Tie2-Cre mice
again did not have anomalous connections of the pulmonary veins, we were surprised to
find that some of these mutants developed transposition of the great arteries (TGA)
(Figure 5.2). As I described earlier in the introductory chapter, TGA is a congenital heart
defect where the aorta and the pulmonary artery fail to connect to the left ventricle and
right ventricle respectively, instead are switched and the aorta connects to the right
atrium and the pulmonary artery connects to the left atrium.

Development of the outflow tract is dependent on proper formation of the endocardial
cushions. The mesenchyme of the endocardial cushions is populated by endothelial cells
that have undergone EMT and migrated into the cardiac jelly and neural crest cells that
have migrated from the dorsal neural tube through the pharyngeal arches. We performed
H&E staining on frontal sections of E11.5 embryos to assess the morphology of the
outflow tract in Pdgfrafl/–;Tie2-Cre and control hearts. We find that the endocardial
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cushions of the anterior outflow tract are hypocellular when compared to controls
(Figure 5.3). At this point our data for investigating the cause of this is preliminary, but it
does not seem like there is a defect in proliferation, apoptosis, or EMT (data not shown),
but we must rigorously continue investigations in this regard to draw conclusions. To
assess the possibility that the lack of cells in the endocardial cushions was due to
improper neural crest migration, we performed in sutu hybridization of a probe for the
neural crest marker plexin A2 (Plxna2) on E11.5 outflow tract sections. Interestingly, we
find that there seems to be a defect or delay in neural crest migration in Pdgfrafl/–;Tie2Cre hearts when compared to control (Figure 5.4).

There is much to do and many questions to answer in elucidating the causes of TGA in
these mutants and the morphogenesis of this disorder. The defects in neural crest
migration in these mutants are an interesting clue in the etiology of TGA, however this is
probably not the whole story. While neural crest ablation and failure of neural crest to
migrate to the outflow tract do result in outflow tract abnormalities such as PTA and
DORV (Kirby and Waldo 1995), these deficiencies do not result in TGA. Further, is not
clear if the hypocellular endocardial cushions are a cause of TGA or resultant from a
separate process. It is interesting that the Pdgfrafl/–;Tie2-Cre develop TGA while the
Pdgfrafl/fl;Tie2-Cre mice do not. While it is clear that Pdgfra in the endothelium is
important in development, it does not seem to be completely necessary in outflow tract
development. In the future it will be important to determine precise expression patterns
and fate-maps of Pdgfra as well as Pdgf ligands during spatially and temporally critical
points. While our investigations are still preliminary, the identification of Pdgfra in
developmental endothelium and resulting TGA in Pdgfra mutants are important
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observations and provide a new tool for investigating this congenital heart defect in the
future.

Future Directions

My studies have largely focused on the role of Sema3d and its receptors ErbB2/Nrp1 in
developmental venous endothelium. It will be of interest to determine if this signaling
pathway plays functional roles in other types of endothelium during development and in
the adult, and whether it also functions in other cell types including cancer cells. ErbB2,
Nrp1, and semaphorins have all been implicated in various malignancies. Multiple
classes of semaphorins have been shown to have both pro- and anti-cancer properties
and are being investigated as therapeutic targets (Tamagnone 2012). ErbB2, also known
as Her2, is an important therapeutic target in a subset of breast cancers (Yu and Hung
2000). ErbB2 overexpression is also seen in gastric and lung cancers (Gravalos and
Jimeno 2008; Grob, Kannengiesser et al. 2012). Similarly, Nrp1 overexpression in breast
and lung cancer is associated with worse outcomes (Hong, Chen et al. 2007; Ghosh,
Sullivan et al. 2008). In fact we find that ErbB2 and Nrp1 are co-expressed in a subset of
tumor vessels in a mouse model of breast cancer (Figure 5.5). In exploring other cell
types we find that ErbB2 and Nrp1 are also co-expressed in the actual tumor cells of
Kras mediated lung tumors in mice (Figure 5.6a). Furthermore, I analyzed gene
expression and survival data from the TCGA Research Network
(http://cancergenome.nih.gov/) and found ErbB2 and Nrp1 expression positively
correlated in lung cancer patients (Figure 5.6b), and those with high ErbB2 and high
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Nrp1 expression had significantly worse overall survival than those with low levels of
both (Figure 5.6c).

One of the biggest successes in breast cancer treatment has been specifically targeting
ErbB2 overexpressing cancers with the humanized monoclonal antibody trastuzumab
(Herceptin, Genentech/Roche)(Hudis 2007). Herceptin works by binding to ErbB2 and
inhibiting dimerization, signaling to intercellular molecules (Akt, Mapk), and/or proteolytic
cleavage. Herceptin treatment increases both overall and disease free survival in
patients with ErbB2 expressing breast cancers. One of the main problems with this
treatment is that a majority of eligible (ErbB2 overexpressing) patients are initially
resistant to Herceptin, and all patients eventually develop resistance (Vu and Claret
2012).

One model of Herceptin resistance involves expression of truncated ErbB2 fragments
known as p95HER2 (Vu and Claret 2012). p95HER2 is a c-terminally truncated ErbB2
fragment lacking most of the extracellular domain, and in particular the Herceptin
binding epitope. p95HER2 cancers are not able to be targeted by Herceptin and
represent a subtype of ErbB2 expressing breast cancers with an even more aggressive
phenotype. This truncated form also lacks the domain required for ErbB dimerization.
Interestingly, even though p95HER2 lacks the domain required for dimerization to other
ErbB members, as I demonstrated in Chapter 4, Nrp1 requires only a small fragment of
the extracellular domain of ErbB2 to bind. It is possible that a p95HER2 complex exists
in these cancers and may be a possible target for Herceptin resistant p95HER2
truncations for therapy.
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Finding ErbB2 expressed in tumor vasculature is interesting for a number of reasons.
ErbB2 overexpression in tumor is associated with increased angiogenesis and
vascularization (Kumar and Yarmand-Bagheri 2001). This the proposed reasons for this
is that ErbB2 causes the expression of Vegf which in turn induces angiogenesis. Also,
anti-ErbB2 therapies result in decreased angiogenesis supposedly by blocking the
ErbB2-Vegf axis. The observation the ErbB2 is expressed in the endothelial cells of the
tumor vasculature begs for the re-assessment of these hypotheses. Perhaps ErbB2
plays a direct role in tumor endothelium and anti-ErbB2 therapies have and antiangiogenic effect by binding to endothelial cells. It will be important to know whether antiErbB2 therapies block signaling of Sema3d, or if it through a separate pathway. We do
not know any of these things for certain, but at this point warrants further investigation.

Investigating ErbB2 in the adult vasculature may also be very interesting. The cardiotoxic
effects of ErbB2 on the heart are well known (Ewer and Ewer 2015). It has been
assumed that this is because of the targeting ErbB2 directly on the cardiomyocytes.
While this may be the case, if ErbB2 is expressed in adult coronary endothelium like it is
in developmental coronary endothelium, anti-ErbB2 therapies may be having a
destructive role in the coronary vasculature that leads to the heart disease in patients
treated with these therapeutics. In addition, it would be of interest to know what role, if
any, these signaling pathways play in adult vascular remodeling and re-vascularization
following injury.

	
  
	
  

	
  

155	
   	
  

	
  

To map the interaction domains of ErbB2 and Nrp1 we made serial truncations of the
extracellular domain of ErbB2. We found that only a very small portion of the
extracellular domain near the transmembrane site is required for this interaction. In the
future I would like to do a similar series for Nrp1. The Nrp1 consists of 2 CUB domains
(a1,a2; semaphorin binding domains), 2 FV/FVIII domains (b1,b2; Vegf binding
domains), a MAM domain (c) responsible for oligomerization, a transmembrane domain,
and a short intercellular domain that is not thought to signal. It is important to know
where the interaction occurs to properly test its importance. We have not yet definitely
proven that the interaction of ErbB2 and Nrp1 is responsible for the effects we have
seen. To test this, we would need to specifically block the interaction while keeping other
functions of these proteins intact. There are a few ways we can consider achieving this
goal once we have a better understanding of the interacting domain/amino acids. One
way would be to design a monoclonal antibody against the interacting region of one or
both receptors. Incubation with this antibody could specifically block the interaction of
these receptors, while leaving the overall expression, conformation, and alternate
functions intact. We are lucky enough that the interaction takes place on the extracellular
side of the receptor as it allows us to work with live cells. Another possible way would be
to specifically mutate the few critical amino acids necessary for this interaction and
perform in vitro experiments regarding semaphorin as well as other signaling pathways.
For this approach to work, the other functions of the protein would have to remain intact
There are a few caveats with this approach that can be addressed. First is that
overexpression studies have their limitations with regards to gene dosage. This can
potentially be counteracted with mutating the genomic locus, possibly by using CRISPR
technology. Another caveat when mutating a protein is making sure that the protein is
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processed and shuttled properly in the cell. This can be assessed with careful
investigation.

Concluding Remarks

My course during my thesis work has been one of letting the science guide the path and
following what is interesting. When I first began investigating the phenotype of the
Sema3d mouse, I had no clue to the interesting and divergent paths that were in store
for me. My first foray into identifying the signaling receptor for Sema3d led me to
investigating Pdgfra, which turned out to have a completely unrelated but equally
interesting cardiovascular phenotype. This led to a new mouse model for the congenital
heart defect, transposition of the great arteries, and clues to the mechanisms involved in
development of this disorder.

My second attempt at identifying the signaling receptor for Sema3d led me to an unlikely
receptor tyrosine kinase, more well known for its role in cancer than in congenital heart
disease, ErbB2. Though it was indeed unlikely, and raised a lot of questions, the science
kept supporting my hypothesis that Sema3d signaled through ErbB2 in endothelial cells.
We were finally able to definitely test our hypothesis by modeling loss of ErbB2 in
developing endothelium which recapitulated both the anomalous pulmonary venous
connection phenotype of Sema3d nulls, but also the coronary vascular phenotype.
Regarding the coronary venous connection abnormalities seen in the Sema3d null mice,
this phenotype was discovered off-hand when investigating something unrelated in these
mice. I did not know much of coronary patterning at the time, but was surprised to find
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that nothing was know about connections of the coronary veins during development.
Although the coronary veins do not garner as much interest as the coronary arteries,
pursuing this interesting phenotype allowed me to connect more dots regarding Sema3d
signaling to endothelial cells. This also led us to discover a novel binding partner for
ErbB2 in neuropilin 1, and possibly a new way in which we can imagine ErbB signaling.

From where we stand, science is again pointing us in interesting and exciting new
directions. One takeaway I have from my experiences is that I believe that one must be
willing to keep and open mind and try not to let our assumptions and biases restrict our
investigations. With that in mind, I am excited to see where science will take us next.
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Table 5.1
Genotype

Wt cre-

Wt cre+

Het cre-

Het cre+

fl/fl cre-

fl/fl cre+

Observed

7

22

17

34

8

2

Expected

11.25

11.25

22.5

22.5

11.25

11.25

Total – 90
Chi-square – 27.6
P – value – <0.001
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Figure 5.1 Pdgfra is expressed in developmental endothelium
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Figure 5.1 Pdgfra is expressed in developmental endothelium.
Flow cytometry from whole embryo single cell suspensions of E11.5 PdgfraGFP/+
embryos using a no antibody control (a), CD31 antibody alone (b,c), GFP antibody alone
(d,e) or a combination of both (f,g). Histograms represent the distribution of the blue
square gates in each set.
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Figure 5.2 Pdgfra mutants develop transposition of the great arteries.
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Figure 5.2 Pdgfra mutants develop transposition of the great arteries.
Gross anatomy and H&E stained sections of E17.5 and P0 hearts from and PdgfraGFP/flox
(top row) and PdgfraGFP/flox;Tie2-Cre (bottom row). Transposition of the great arteries is
seen in the Pdgfrafl/–;Tie2-Cre hearts but not in the controls.
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Figure 5.3 Hypoplastic endocardial cushions in Pdgfra mutants
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Figure 5.3 Hypoplastic endocardial cushions in Pdgfra mutants.
H&E stained serial section of E11.5 Pdgfraflox/+ (top row) and PdgfraGFP/flox;Tie2-Cre
(bottom row) hearts showing frontal and sagittal views of the outflow tract. Significant
hypoplasia is evident in the anterior outflow tract of the PdgfraGFP/flox;Tie2-Cre hearts.
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Figure 5.4 Neural crest migration is disturbed in Pdgfra mutants
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Figure 5.4 Neural crest migration is disturbed in Pdgfra mutants.
In situ hybridization of a probe for the neural crest marker plexin A2 on E11.5 Pdgfraflox/+
(top row) and PdgfraGFP/flox;Tie2-Cre (bottom row) hearts. Fewer plexin A2 positive neural
crest cells are present in the endocardial cushions of the PdgfraGFP/flox;Tie2-Cre outflow
tract (arrows).
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Figure 5.5 ErbB2 and Nrp1 are co-expressed on endothelial cells in mammary
tumors
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Figure 5.5 ErbB2 and Nrp1 are co-expressed on endothelial cells in mammary
tumors.
Section from a mouse mammary tumor co-stained for Pecam1 (blue), ErbB2 (green),
and Nrp1 (red).
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Figure 5.6 ErbB2 and Nrp1 are co-expressed in lung tumors
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Figure 5.6 ErbB2 and Nrp1 are co-expressed in lung tumors.
(a) Section from a HopxER-Cre/+;K-RasG12D;R26mT-mG/+ lung tumor immunostained for ErbB2
(green) and Nrp1 (red). (b) Correlation of ErbB2 and Nrp1 expression from 1130 patients
with lung cancer. (c) Kaplan-Meier survival curve comparing lung cancer patient that
express high levels of ErbB2 and Nrp1 (n=352) vs low levels of ErbB2 and Nrp1
(n=339). Scale bars = 100μm
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